Stanford



Robert Negrin

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

NIH Biosketch available Online

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

  875 Blake Wilbur Dr Clinic F

  MC 6560

  Stanford, CA 94305

  Tel (650) 498-6000 **Fax** (650) 498-6159

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

  Kimberly Baker - Administrative Associate

  Email kbaker5@stanford.edu

Bio

BIO

Robert S. Negrin, MD is a Professor of Medicine and former Chief of the Division of Blood and Marrow Transplantation at Stanford University from 2000-2020. He received his undergraduate degree from the University of California at Berkeley and MD from Harvard University. He trained in medicine and hematology at Stanford University and joined the faculty in 1990. His research work has focused on cellular immunology in particular developing a more fundamental understanding of complex biological reactions such as graft versus host and graft vs tumor reactions in animal models and in the clinic. He has authored over 300 original papers, 40 book chapters and a book. He has received a number of awards including the Doris Duke Distinguished Clinical Scientist Award and is a member of the Association of American Physicians. He was previously the President of the International Society of Cellular Therapy and the American Society of Blood and Marrow Transplantation. He served as an Associate Editor of the journal Blood and is the founding editor of Blood Advances. He is the President Elect of the American Society of Hematology in 2025 and President in 2026.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Cancer > Hematology
- Blood and Marrow Transplantation
- Hematology

ACADEMIC APPOINTMENTS

- Professor, Medicine - Blood & Marrow Transplantation
- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Division Chief, Blood and Marrow Transplant Program, Stanford University, (2000-2020)

- Medical Director, Clinical Bone Marrow Transplantation Laboratory, (1990-2011)

HONORS AND AWARDS

- Associate Editor, Blood (2010-2017)
- Member, Association of American Physicians (AAP) (2008)
- President, American Society of Blood and Marrow Transplantation (2006-2007)
- Distinguished Clinical Scientist Award, Doris Duke Foundation (2004-2009)
- President, International Society of Cellular Therapy (2000-2002)
- Fellow, Jose Carreras International Leukemia Foundation (1993-1996)
- Fellowship, Damon Runyon-Walter Winchell Cancer Fund (1988-1991)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Hematology
- Editor in Chief, Blood Advances (2017 - present)
- Member, International Society of Experimental Hematology
- Member, American College of Physicians
- Member, American Association for the Advancement of Science
- Member, International Society for Cellular Therapy
- Member, American Society for Blood and Marrow Transplantation

PROFESSIONAL EDUCATION

- Internship: Stanford University School of Medicine (1985) CA
- Board Certification: Hematology, American Board of Internal Medicine (2024)
- Fellowship: Stanford University School of Medicine (1987) CA
- Residency: Stanford University School of Medicine (1986) CA
- Board Certification: Internal Medicine, American Board of Internal Medicine (1987)
- Medical Education: Harvard Medical School (1984) MA
- BA, Univ. California, Berkeley , Biochemistry (1977)

COMMUNITY AND INTERNATIONAL WORK

- Volunteer

LINKS

- Video Story: https://stanfordhealthcare.org/stanford-health-care-now/why-i-got-into-medicine/why-medicine-robert-negrin-md.html
- Get a Second Opinion: https://stanfordhealthcare.org/second-opinion/overview.html

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Research projects in our laboratory are aimed at studying the biology of cell populations capable of inducing or suppressing graft vs host disease as well as cells capable of promoting a graft vs tumor effect. In particular we are studying:

1) The clinical utility of expanded cytotoxic cells for immunotherapy. We have developed animal models utilizing mice with severe combined immunodeficiency (SCID) which will accept human tumor cells or murine model systems of syngeneic and allogeneic transplantation. In some instances the tumor cells are transfected with the bioluminescent marker luciferase so that the tumor cell growth can be quantitatively tracked in living animals. Using these model system we are studying the clinical efficacy of the expanded cytotoxic cells.

2) The interaction between the cytotoxic effector cells and a variety of tumor cell targets is under study. The role of granzyme/perforin and fas mediated pathways as well as the cell surface molecule NKG2D in cytotoxicity is under study.

3) We are exploring the biological impact of phenotypically defined populations of regulatory T cells on graft vs host disease and graft vs tumor reactions.

4) We are utilizing bioluminescent techniques to study these complex biological processes by either labelling the tumor or effector cell populations with the light emitting luciferase gene such that small numbers of cells can be tracked non-invasively, sensively and quantitatively.

CLINICAL TRIALS

- A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1), Not Recruiting
- A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML), Not Recruiting
- Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102), Not Recruiting
- Axicabtagene Ciloleucel Expanded Access Study, Not Recruiting
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma, Not Recruiting
- CT Antigen TCR-redirected T Cells for Ovarian Cancer., Not Recruiting
- Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation, Not Recruiting
- Detection of Graft Versus Host Disease With [18F]F-AraG, Not Recruiting
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation, Not Recruiting
- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant, Not Recruiting
- Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma, Not Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Not Recruiting
- Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies, Not Recruiting
- Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD), Not Recruiting
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant, Not Recruiting
- Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML, Not Recruiting
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203), Not Recruiting
- Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation, Not Recruiting
- Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell, Not Recruiting
- Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies, Not Recruiting
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors, Not Recruiting
- Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting

- Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Recruiting
- Transplantation for Patients With Chronic Lymphocytic Leukemia, Not Recruiting
- Bone Marrow Grafting for Leukemia and Lymphoma, Not Specified

Teaching

STANFORD ADVISEES

Doctoral Dissertation Reader (AC)

George Wythes

Postdoctoral Faculty Sponsor

Cameron Bader, Phil Kim

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (PhD Program)
- Immunology (PhD Program)
- Medicine (Masters Program)

Publications

PUBLICATIONS

- **CD4+CD25+FOXP3+ Regulatory T Cells to Protect Against Graft Versus Host Disease.** *Blood*
  Negrin, R. S., Meyer, E.
  2026
- **Regulatory-like FOXP3⁺Helios⁺CD4⁺ T conventional cells correlate with T-cell activation after Orca-T immunotherapy** *BLOOD*
  Bader, C. S., Killian, S., Iliopoulou, B. P., Chen, P., Pathak, S., Le, C. T., Villar-Prados, A., Ji, X., Jensen, K. P., Negrin, R. S., Meyer, E. H.
  2026; 147 (21): 2489-2502
- **Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.** *Transplantation and cellular therapy*
  Molina, A., Bubb, Q. R., Srinagesh, H. K., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, et al
  2026
- **Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.** *Blood*
  Bader, C. S., Killian, S., Iliopoulou, B. P., Chen, P. I., Pathak, S., Le, C. T., Villar-Prados, A., Ji, X., Jensen, K. P., Negrin, R. S., Meyer, E.
  2026
- **Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.** *Blood*
  Meyer, E., Salhotra, A., Gandhi, A., Pantin, J., Patel, S. S., Hoeg, R. T., Gomez-Arteaga, A., Faramand, R. G., Tamari, R., Waller, E. K., Kosuri, S., Jimenez Jimenez, A. M., Holter-Chakrabarty, et al
  2025
- **Regulatory T cell approaches for graft-versus-host disease prevention.** *Current opinion in immunology*
  Bader, C. S., Meyer, E. H., Negrin, R. S.
  2025; 98: 102685
- **A Randomized Phase 3 Trial in Patients with Hematologic Malignancies Demonstrates Improved Survival Free of Chronic GVHD with Orca-T® Compared to Conventional Allogeneic Hematopoietic Stem Cell Transplant**
  Faramand, R., Salhotra, A., Gandhi, A., Pantin, J., Patel, S., Hoeg, R., Gomez-Arteaga, A., Tamari, R., Kosuri, S., Jimenez, A., Holter-Chakrabarty, J., Dholaria, B., Chen, et al
  CIG MEDIA GROUP, LP.2025

- **Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.** *Blood advances*
  Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., Negrin, R. S., Shiraz, P., Smith, M., Bharadwaj, S., Weng, W. K., Kennedy, V. E., Dahiya, et al
  2025

- **Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues.** *Cell reports*
  Jayasinghe, R. G., Hollingsworth, D., Schedler, N. C., Landy, E., Boonchalermvichian, C., Gupta, B., Yan, H., Baker, J., Dejene, B., Weinberg, K. I., Negrin, R. S., Mavers, M.
  2025; 44 (5): 115587

- **Durable reconstitution of sinonasal epithelium by transplant of CFTR gene corrected airway stem cells.** *bioRxiv : the preprint server for biology*
  Bravo, D. T., Vaidyanathan, S., Baker, J., Sinha, V., Tsai, E., Roozdar, P., Kong, W. W., Atkinson, P. J., Patel, Z. M., Hwang, P. H., Rao, V. K., Negrin, R. S., Wine, et al
  2025

- **Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.** *Blood*
  Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., Kim, P., Sutherland, K. C., Bharadwaj, S., Dahiya, S., Frank, M. J., Arai, S., Johnston, et al
  2025

- **PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS**
  Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, S., Shiraz, et al
  SPRINGERNATURE.2024: 287-288

- **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
  Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
  2024

- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*
  Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al
  2024

- **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*
  Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al
  2024; 12 (7)

- **invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies.** *Frontiers in transplantation*
  Boonchalermvichian, C., Yan, H., Gupta, B., Rubin, A., Baker, J., Negrin, R. S.
  2024; 3: 1353803

- **Extracellular release of mitochondria induced by pre-hematopoietic stem cell transplant conditioning exacerbates GVHD.** *Blood advances*
  Vijayan, V., Yan, H., Lohmeyer, J. K., Prentiss, K. A., Patil, R. V., Barbarito, G., Lopez, I., Elezaby, A., Peterson, K., Baker, J., Ostberg, N. P., Bertaina, A., Negrin, et al
  2024

- **Management of post-autologous transplant relapse in patients with T-cell lymphomas.** *American journal of hematology*
  Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Shizuru, J., Meyer, E., Muffly, L., Rezvani, A. R., Shiraz, P., Sidana, S., Dahiya, et al
  2024

- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
  Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al

2024

- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*
  Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al
  2024

- **Molecular Imaging of Acute Graft-Versus-Host Disease.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Bernardi, C., Garibotto, V., Mobashwera, B., Negrin, R. S., Alam, I. S., Simonetta, F.
  2024

- **Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.** *Blood advances*
  Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., Johnston, L. J., Rezvani, A. R., Weng, W. K., Miklos, D. B., Frank, M. J., Tamaresis, J. S., Agrawal, et al
  2023

- **Single-cell Transcriptomics Reveal Different Maturation Stages and Sublineages Commitment of Human Thymic Invariant Natural Killer T cells.** *Journal of leukocyte biology*
  Maas-Bauer, K., Köhler, N., Stell, A. V., Zwick, M., Acharya, S., Rensing-Ehl, A., König, C., Kroll, J., Baker, J., Koßmann, S., Pradier, A., Wang, S., Docquier, et al
  2023

- **Analysis of the T-cell repertoire and transcriptome identifies mechanisms of regulatory T-cell suppression of GVHD** *BLOOD*
  Lohmeyer, J. K., Hirai, T., Turkoz, M., Buhler, S., Ramos, T., Koehler, N., Baker, J., Melotti, A., Wagner, I., Pradier, A., Wang, S., Ji, X., Becattini, et al
  2023; 141 (14): 1755-1767

- **Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.** *Blood*
  Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., Frank, M. J., Johnston, L. J., Miklos, D. B., Muffly, L., Negrin, R. S., Rezvani, A. R., Shiraz, et al
  2023

- **Analysis of T cell Repertoire and Transcriptome Identifies Mechanisms of Regulatory T cell (Treg) Suppression of GvHD.** *Blood*
  Lohmeyer, J. K., Hirai, T., Turkoz, M., Buhler, S., Lopes Ramos, T., Kohler, N., Baker, J., Melotti, A., Wagner, I., Pradier, A., Wang, S., Ji, X., Becattini, et al
  2022

- **Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rbeta system to selectively expand regulatory T-cells in vivo.** *Blood*
  Lopes Ramos, T., Bolivar-Wagers, S., Jin, S., Thangavelu, G., Simonetta, F., Lin, P., Hirai, T., Saha, A., Koehn, B. H., L Su, L., Picton, L. K., Baker, J., Lohmeyer, et al
  2022

- **IL-2 receptor engineering enhances regulatory T cell function suppressed by calcineurin inhibitor.** *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*
  Hirai, T., Lin, P., Ramos, T. L., Simonetta, F., Su, L. L., Picton, L. K., Baker, J., Lohmeyer, J. K., Garcia, K. C., Negrin, R. S.
  2022

- **ICOS ImmunoPET Enables Visualization of Activated T Cells and Early Diagnosis of Murine Acute Gastrointestinal GvHD.** *Blood advances*
  Xiao, Z., Alam, I. S., Simonetta, F., Chen, W., Scheller, L., Murty, S., Lohmeyer, J. K., Lopes Ramos, T. L., James, M. L., Negrin, R. S., Gambhir, S. S.
  2022

- **Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies.** *ACS central science*
  Xie, J., El Rami, F., Zhou, K., Simonetta, F., Chen, Z., Zheng, X., Chen, M., Balakrishnan, P. B., Dai, S., Murty, S., Alam, I. S., Baker, J., Negrin, et al
  2022; 8 (5): 590-602

- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.** *Transplantation and cellular therapy*
  Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R., Rezvani, et al
  2022

- **Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.** *Transplantation and cellular therapy*
  Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M. L., Lowsky, R., Brown, J. W., Johnston, L., Rezvani, A. R., Frank, et al
  1800
- **Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy** *BLOOD ADVANCES*
  Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, et al
  2021; 5 (21): 4465-4475
- **Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients.** *Blood advances*
  Jensen, K. P., Hongo, D., Ji, X., Zheng, P., Pawar, R. D., Wu, H., Busque, S., Scandling, J. D., Shizuru, J. A., Lowsky, R., Shori, A., Dutt, S., Waters, et al
  2021
- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
  Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
  2021; 5 (16): 3147-3151
- **Allogeneic CAR-invariant Natural Killer T Cells Exert Potent Antitumor Effects Through Host CD8 T Cell Cross-Priming.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Simonetta, F., Lohmeyer, J. K., Hirai, T., Maas-Bauer, K., Alvarez, M., Wenokur, A. S., Baker, J., Aalipour, A., Ji, X., Haile, S. T., Mackall, C. L., Negrin, R.
  2021
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*
  Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al
  2021
- **A fructo-oligosaccharide prebiotic is well-tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial.** *Transplantation and cellular therapy*
  Andermann, T. M., Fouladi, F., Tamburini, F. B., Sahaf, B., Tkachenko, E., Greene, C., Buckley, M. T., Brooks, E. F., Hedlin, H., Arai, S., Mackall, C. L., Miklos, D., Negrin, et al
  2021
- **Imaging alloreactive T cells provides early warning of organ transplant rejection.** *JCI insight*
  Hirai, T., Mayer, A. T., Nobashi, T. W., Lin, P., Xiao, Z., Udagawa, T., Seo, K., Simonetta, F., Baker, J., Cheng, A. G., Negrin, R. S., Gambhir, S. S.
  2021; 6 (13)
- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
  Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
  2021
- **Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report**
  Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M., Lowsky, R., Brown, J., Johnston, L., Rezvani, A., Frank, M., Muffly, et al
  SPRINGERNATURE.2021: 181
- **Invariant Natural Killer T Cell Subsets Have Diverse Graft-Versus-Host-Disease-Preventing and Anti-Tumor Effects.** *Blood*
  Maas-Bauer, K., Lohmeyer, J. K., Hirai, T., Lopes Ramos, T., Fazal, F. M., Litzenburger, U. M., Yost, K. E., Ribado, J. V., Kambham, N., Wenokur, A., Lin, P., Alvarez, M., Mavers, et al
  2021

- **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*
  Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al
  2021

- **Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance.** *The Journal of clinical investigation*
  Hirai, T., Ramos, T. L., Lin, P., Simonetta, F., Su, L. L., Picton, L. K., Baker, J., Lin, J., Li, P., Seo, K., Lohmeyer, J. K., Wagers, S. B., Mavers, et al
  2021; 131 (8)

- **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
  Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al
  2021

- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.** *Blood advances*
  Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
  2021; 5 (1): 143-155

- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*
  Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
  2021; 5 (1): 143–55

- **Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.** *Blood advances*
  Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., Shizuru, J. A., Lowsky, R., Meyer, et al
  2021

- **Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD.** *Blood advances*
  Hirai, T., Lin, P. Y., Simonetta, F., Maas-Bauer, K., Turkoz, M., Mavers, M., Baker, J., Negrin, R. S.
  2021; 5 (11): 2528-2538

- **Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Simonetta, F., Alam, I. S., Lohmeyer, J. K., Sahaf, B., Good, Z., Chen, W., Xiao, Z., Hirai, T., Scheller, L., Engels, P., Vermesh, O., Robinson, E., Haywood, et al
  2020

- **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
  Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al
  2020

- **Visualization of activated T cells by OX40-immunoPET as a strategy for diagnosis of acute Graft-versus-Host-Disease.** *Cancer research*
  Alam, I. S., Simonetta, F., Scheller, L., Mayer, A. T., Murty, S., Vermesh, O., Nobashi, T. W., Lohmeyer, J. K., Hirai, T., Baker, J., Lau, K. H., Negrin, R., Gambhir, et al
  2020

- **MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors.** *JCI insight*
  Marschner, D., Falk, M., Javorniczky, N. R., Hanke-Muller, K., Rawluk, J., Schmitt-Graeff, A., Simonetta, F., Haring, E., Dicks, S., Ku, M., Duquesne, S., Aumann, K., Rafei-Shamsabadi, et al
  2020

- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**

Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al

ELSEVIER SCIENCE INC.2020: S106

- **Engineered IL-2 Cytokine-Cytokine Receptor Complex Enables Selective Expansion of Regulatory T Cells and Facilitates Establishment of Organ Transplantation Tolerance**

  Hirai, T., Simonetta, F., Su, L. L., Picton, L., Baker, J., Seo, K., Lohmeyer, J., Mavers, M., Blazar, B. R., Garcia, C., Negrin, R. S.

  ELSEVIER SCIENCE INC.2020: S59–S60

- **Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming**

  Simonetta, F., Hirai, T., Lohmeyer, F., Maas-Bauer, K., Alvarez, M., Wenokur, A., Baker, J., Aalipour, A., Haile, S., Mackall, C. L., Negrin, R. S.

  ELSEVIER SCIENCE INC.2020: S42

- **High-Parametric Evaluation of Human Invariant Natural Killer T Cells to Delineate Heterogeneity in Allo- and Autoimmunity.** *Blood*

  Erkers, T., Xie, B., Kenyon, L. J., Smith, B., Rieck, M., Jensen, K. P., Ji, X., Basina, M., Strober, S., Negrin, R. S., Maecker, H. T., Meyer, E.

  2020

- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*

  Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al

  2020; 217 (9)

- **Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET** *Clinical cancer research: an official journal of the American Association for Cancer Research*

  Alam*, I. S., Simonetta*, F.

  2020: 1058–68

- **A novel antibody-cell conjugation method to enhance and characterize cytokine-induced killer cells.** *Cytotherapy*

  Frank, M. J., Olsson, N. n., Huang, A. n., Tang, S. W., Negrin, R. S., Elias, J. E., Meyer, E. H.

  2020; 22 (3): 135–43

- **Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.** *Frontiers in immunology*

  Alvarez, M., Pierini, A., Simonetta, F., Baker, J., Maas-Bauer, K., Hirai, T., Negrin, R. S.

  2020; 11: 614250

- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*

  Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al

  2020

- **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*

  Weng, W. K., Arai, S. n., Rezvani, A. n., Johnston, L. n., Lowsky, R. n., Miklos, D. n., Shizuru, J. n., Muffly, L. n., Meyer, E. n., Negrin, R. S., Wang, E. n., Almazan, T. n., Million, et al

  2020; 4 (18): 4474–82

- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*

  Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al

  2020

- **Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant.** *Blood advances*

  Zheng, P. n., Tamaresis, J. n., Thangavelu, G. n., Xu, L. n., You, X. n., Blazar, B. R., Negrin, R. S., Zehnder, J. L., Iliopoulou, B. P., Meyer, E. H.

  2020; 4 (17): 4232–43

- **Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.** *Frontiers in immunology*

  Alvarez, M., Simonetta, F., Baker, J., Morrison, A. R., Wenokur, A. S., Pierini, A., Berraondo, P., Negrin, R. S.

  2020; 11: 7

- **Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming**
  Simonetta, F., Hirai, T., Lohmeyer, J. K., Maas-Bauer, K., Alvarez, M., Wenokur, A. S., Baker, J., Haile, S., Mackall, C. L., Negrin, R. S.
  AMER SOC HEMATOLOGY.2019

- **Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease** *FRONTIERS IN IMMUNOLOGY*
  Mavers, M., Simonetta, F., Nishikii, H., Ribado, J., Maas-Bauer, K., Alvarez, M., Hirai, T., Turkoz, M., Baker, J., Negrin, R. S.
  2019; 10

- **Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.** *Frontiers in immunology*
  Mavers, M., Simonetta, F., Nishikii, H., Ribado, J. V., Maas-Bauer, K., Alvarez, M., Hirai, T., Turkoz, M., Baker, J., Negrin, R. S.
  2019; 10: 1624

- **Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Narayan, R., Benjamin, J. E., Shah, O., Tian, L., Tate, K., Armstrong, R., Xie, B. J., Lowsky, R., Laport, G., Negrin, R. S., Meyer, E. H.
  2019; 25 (7): 1293–1303

- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients** *JCI INSIGHT*
  Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., Tang, S., Baker, J., Armstrong, R., Tate, K., Tadisco, C., Arai, S., Johnston, et al
  2019; 4 (10)

- **Prognostic score and cytogenetic risk classification for chronic lymphocytic leukemia patients: Center for International Blood and Marrow Transplant Research report.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Kim, H. T., Ahn, K. W., Hu, Z. H., Davids, M. S., Volpe, V. n., Antin, J. H., Sorror, M. n., Shadman, M. n., Press, O. W., Pidala, J. n., Hogan, W. n., Negrin, R. n., Devine, et al
  2019

- **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*
  Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al
  2019; 3 (16): 2454–64

- **Immune regulation in hematopoietic cell transplantation.** *Bone marrow transplantation*
  Negrin, R. S.
  2019; 54 (Suppl 2): 765–68

- **Donor-derived CIK Cell Infusion as Consolidation after Non-myeloablative Allogeneic Transplant for Myeloid Neoplasms.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
  Narayan, R. n., Benjamin, J. E., Shah, O. n., Tian, L. n., Tate, K. n., Armstrong, R. n., Xie, B. n., Lowsky, R. n., Laport, G. n., Negrin, R. S., Meyer, E. H.
  2019

- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.** *JCI insight*
  Meyer, E. H., Laport, G. n., Xie, B. J., MacDonald, K. n., Heydari, K. n., Sahaf, B. n., Tang, S. W., Baker, J. n., Armstrong, R. n., Tate, K. n., Tadisco, C. n., Arai, S. n., Johnston, et al
  2019; 4 (10)

- **Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway.** *JCI insight*
  Alvarez, M. n., Simonetta, F. n., Baker, J. n., Pierini, A. n., Wenokur, A. S., Morrison, A. R., Murphy, W. J., Negrin, R. S.
  2019; 5

- **Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort**
  Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, et al
  AMER SOC HEMATOLOGY.2018

- **A Proinflammatory Invariant Natural Killer T Cells Phenotypic State Associates with Human Graft-Versus-Host Disease Onset and Response**
  Erkers, T., Xei, B., Kenyon, L., Rieck, M., Basina, M., Jensen, K., Strober, S., Negrin, R. S., Maecker, H. T., Meyer, E. H.
  AMER SOC HEMATOLOGY.2018

- **Invariant Natural Killer T Cell Subsets Have Diverse Functions: iNKT2 and iNKT17 Protect from Graft-Versus-Host-Disease, Whereas iNKT1 Have Antitumor Potential**
  Maas-Bauer, K., Simonetta, F., Hirai, T., Wenokur, A., Fazal, F., Kambham, N., Ribado, J., Mavers, M., Baker, J., Bhatt, A. S., Chang, H. Y., Negrin, R. S.
  AMER SOC HEMATOLOGY.2018

- **Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma**
  Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., Latchford, T., Villa, B., Cancilla, J., Oak, J., Natkunam, Y., Long, S. R., Arai, et al
  AMER SOC HEMATOLOGY.2018

- **Tracking T Cell Activation By OX40 Immuno-PET: A Novel Strategy for Imaging of Graft Versus Host Disease**
  Simonetta, F., Alam, I. S., Mayer, A. T., Murty, S., Vermesh, O., Hirai, T., Nobashi, T., Lau, K., Gambhir, S. S., Negrin, R. S.
  AMER SOC HEMATOLOGY.2018

- **Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution.** *Oncotarget*
  Kellner, J. N., Delemarre, E. M., Yvon, E., Nierkens, S., Boelens, J. J., McNiece, I., Olson, A., Nieto, Y., Ciurea, S., Popat, U., Ahmed, S., Champlin, R., Ramos, et al
  2018; 9 (86): 35611–22

- **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*
  Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
  2018; 2 (6): 681–90

- **Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells** *NATURE MEDICINE*
  Mathew, N. R., Baumgartner, F., Braun, L., O'Sullivan, D., Thomas, S., Waterhouse, M., Mueller, T. A., Hanke, K., Taromi, S., Apostolova, P., Illert, A. L., Melchinger, W., Duquesne, et al
  2018; 24 (3): 282-+

- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al
  2017; 23 (10): 1744–48

- **A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant.** *Cancer research*
  Ronald, J. A., Kim, B., Gowrishankar, G., Namavari, M., Alam, I. S., D'Souza, A., Nishikii, H., Chuang, H., Ilovich, O., Lin, C., Reeves, R., Shuhendler, A., Hoehne, et al
  2017; 77 (11): 2893-2902

- **Foxp3(+) regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis** *NATURE COMMUNICATIONS*
  Pierini, A., Nishikii, H., Baker, J., Kimura, T., Kwon, H., Pan, Y., Chen, Y., Alvarez, M., Strober, W., Velardi, A., Shizuru, J. A., Wu, J. Y., Chiba, et al
  2017; 8

- **Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation** *FRONTIERS IN IMMUNOLOGY*
  Simonetta, F., Alvarez, M., Negrin, R. S.
  2017; 8

- **Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells.** *Blood*
  Du, J., Paz, K., Thangavelu, G., Schneidawind, D., Baker, J., Flynn, R., Duramad, O., Feser, C., Panoskaltsis-Mortari, A., Negrin, R. S., Blazar, B. R.
  2017

- **Increased Foxp3(+)Helios(+) Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Chen, Y., Efebera, Y. A., Johnston, L., Ball, E. D., Avigan, D., Lekakis, L. J., Bachier, C. R., Martin, P., Duramad, O., Ishii, Y., Han, S., Jung, Y., Lee, et al
  2017; 23 (4): 625-634

- **Repertoire of Murine T Cells in Target Tissues of MHC-Matched and -Mismatched Graft-Versus-Host Disease**
  Zheng, P., You, X., Tamaresis, J., Xu, L., Hsu, K., Than, R., Iliopoulou, B. P., Pierini, A., Schneidawind, D., Zehnder, J. L., Blazar, B. R., Negrin, R. S., Meyer, et al
  ELSEVIER SCIENCE INC.2017: S307–S308

- **Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.** *Biology of blood and marrow transplantation*
  Chen, Y., Efebera, Y. A., Johnston, L., Ball, E. D., Avigan, D., Lekakis, L. J., Bachier, C. R., Martin, P., Duramad, O., Ishii, Y., Han, S., Jung, Y., Lee, et al
  2017

- **T cells expressing chimeric antigen receptor promote immune tolerance.** *JCI insight*
  Pierini, A. n., Iliopoulou, B. P., Peiris, H. n., Pérez-Cruz, M. n., Baker, J. n., Hsu, K. n., Gu, X. n., Zheng, P. P., Erkers, T. n., Tang, S. W., Strober, W. n., Alvarez, M. n., Ring, et al
  2017; 2 (20)

- **Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation.** *Frontiers in immunology*
  Mavers, M., Maas-Bauer, K., Negrin, R. S.
  2017; 8: 900

- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*
  Spinner, M. A., Fernández-Viña, M. n., Creary, L. E., Quinn, O. n., Elder, L. n., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al
  2017; 1 (17): 1347–57

- **The Use of Monoclonal Antibody Directed Chimeric Antigen Receptors to Facilitate Conventional T Cell and Treg Control of GvHD and Tissue Tolerance in Murine Models**
  Pierini, A., Iliopoulou, B., Peiris, H., Cruz, M., Baker, J., Hsu, K., Strober, W., Zheng, P., Erkers, T., Ring, A., Velardi, A., Negrin, R. S., Kim, et al
  AMER SOC HEMATOLOGY.2016

- **Foxp3(+) regulatory T Cells Maintain Bone Marrow Microenvironment for B Cell Differentiation from Hematopoietic Stem Cells**
  Nishikii, H., Pierini, A., Yokoyama, Y., Kimura, T., Kwon, H., Alvarez, M., Baker, J., Shizuru, J., Wu, J., Chiba, S., Negrin, R. S.
  AMER SOC HEMATOLOGY.2016

- **A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease**
  Johnston, L., Armstrong, R., Baker, J., Sahaf, B., Otani, J., Tate, K., Tudisco, C., Sheehan, K., Meyer, E., Miklos, D., Negrin, R. S.
  AMER SOC HEMATOLOGY.2016

- **DR3 Signaling Modulates the Function of Foxp3(+) regulatory T Cells and the Severity of Acute Graft and Host Disease**
  Nishikii, H., Byung-Su, K., Chen, Y., Baker, J., Pierini, A., Alvarez, M., Mavers, M., Maas-Bauer, K., Negrin, R. S.
  AMER SOC HEMATOLOGY.2016

- **A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease**
  Johnston, L., Armstrong, R., Baker, J., Sahaf, B., Otani, J., Tate, K., Tudisco, C., Sheehan, K., Meyer, E., Miklos, D., Negrin, R. S.
  AMER SOC HEMATOLOGY.2016

- **DR3 Signaling Modulates the Function of Foxp3(+) regulatory T Cells and the Severity of Acute Graft and Host Disease**
  Nishikii, H., Byung-Su, K., Chen, Y., Baker, J., Pierini, A., Alvarez, M., Mavers, M., Maas-Bauer, K., Negrin, R. S.
  AMER SOC HEMATOLOGY.2016

- **Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning.** *Journal of immunology*

Müller, A. M., Florek, M., Kohrt, H. E., Küpper, N. J., Filatenkov, A., Linderman, J. A., Hadeiba, H., Negrin, R. S., Shizuru, J. A.
2016; 197 (10): 4151-4162

- **Introduction to a review series: Chronic GVHD - from pathogenic BCR signaling to novel therapeutic targets.** *Blood*
  Zeiser, R., Negrin, R. S.
  2016
- **DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft versus host disease.** *Blood*
  Nishikii, H., Kim, B., Yokoyama, Y., Chen, Y., Baker, J., Pierini, A., Alvarez, M., Mavers, M., Maas-Bauer, K., Pan, Y., Chiba, S., Negrin, R. S.
  2016
- **TNF-a priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.** *Blood*
  Pierini, A., Strober, W., Moffett, C., Baker, J., Nishikii, H., Alvarez, M., Pan, Y., Schneidawind, D., Meyer, E., Negrin, R. S.
  2016; 128 (6): 866-871
- **Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma.**
  Neppalli, A., Shizuru, J., Johnston, L. J., Muffly, L. S., Weng, W., Negrin, R., Meyer, E., Laport, G., Lowsky, R., Arai, S., Miklos, D., Rezvani, A. R.
  AMER SOC CLINICAL ONCOLOGY.2016
- **Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation.**
  Veeraputhiran, M., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L. S., Negrin, R., Rezvani, A. R., Shizuru, J., Weng, W., Johnston, L. J.
  AMER SOC CLINICAL ONCOLOGY.2016
- **TNF-Alpha Priming Enhances CD4+FoxP3+Regulatory T Cell Suppressive Function in GVHD Prevention and Treatment**
  Pierini, A., Strober, W. A., Moffett, C., Baker, J., Nishikii, H., Pan, Y., Alvarez, M., Schneidawind, D., Meyer, E., Negrin, R.
  ELSEVIER SCIENCE INC.2016: S144–S145
- **Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin**
  Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W., Arai, S., Johnston, L., Laport, G. G., Shizuru, J. A., Negrin, R., Strober, S., Lowsky, et al
  ELSEVIER SCIENCE INC.2016: S204–S205
- **Immune Characterization of Ibrutinib Therapy Following Allohct That Provides GVL Benefit without Gvhd**
  Sahaf, B., Ryan, C. E., Rezvani, A., Nakasone, H., Otani, J., Coutre, S., Lowsky, R., Negrin, R., Miklos, D. B.
  ELSEVIER SCIENCE INC.2016: S412
- **Impact of Donor T Cells on NK Cell Development after Allogeneic Hematopoietic Cell Transplantation**
  Alvarez, M., Pierini, A., Baker, J., Negrin, R.
  ELSEVIER SCIENCE INC.2016: S149–S150
- **The Use of Monoclonal Antibody Directed Chimeric Antigen Receptors to Guide T Cell and Treg Homing for GvHD Control and Tissue Tolerance in Murine Models**
  Pierini, A., Iliopoulou, B. P., Baker, J., Peiris, H., Hsu, K., Kim, S., Negrin, R., Meyer, E.
  ELSEVIER SCIENCE INC.2016: S88–S89
- **Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization.** *Proceedings of the National Academy of Sciences of the United States of America*
  Kuipers, H. F., Rieck, M., Gurevich, I., Nagy, N., Butte, M. J., Negrin, R. S., Wight, T. N., Steinman, L., Bollyky, P. L.
  2016; 113 (5): 1339-1344
- **Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization.** *Proceedings of the National Academy of Sciences of the United States of America*
  Kuipers, H. F., Rieck, M., Gurevich, I., Nagy, N., Butte, M. J., Negrin, R. S., Wight, T. N., Steinman, L., Bollyky, P. L.
  2016
- **NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment.** *Stem cells international*
  Pierini, A., Alvarez, M., Negrin, R. S.
  2016; 2016: 9025835-?

- **Freeze and Thaw of CD4(+) CD25(+) Foxp3(+) Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease** *PLOS ONE*
  Florek, M., Schneidawind, D., Pierini, A., Baker, J., Armstrong, R., Pan, Y., Leveson-Gower, D., Negrin, R., Meyer, E.
  2015; 10 (12)

- **Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Kurnellas, M. P., Ghosn, E. E., Schartner, J. M., Baker, J., Rothbard, J. J., Negrin, R. S., Herzenberg, L. A., Fathman, C. G., Steinman, L., Rothbard, J. B.
  2015; 112 (49): 15016-15023

- **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**
  Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al
  AMER SOC HEMATOLOGY.2015

- **Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms**
  Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., Galvez, L., Armstrong, R., Sheehan, K., Lowsky, R., Arai, S., Johnston, L., Miklos, et al
  AMER SOC HEMATOLOGY.2015

- **Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility Barriers**
  Zheng, P., Vasey, A. E., Baker, J., Iliopoulou, B., Leveson-Gower, D. B., Pierini, A., Schneidawind, D., You, X., Hsu, K., Negrin, R., Meyer, E.
  AMER SOC HEMATOLOGY.2015

- **Expanded CD4+Foxp3+Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation**
  Nishikii, H., Kim, B., Yokoyama, Y., Baker, J., Pierini, A., Alvarez, M., Pan, Y., Chen, Y., Schneidawind, D., Chiba, S., Negrin, R.
  AMER SOC HEMATOLOGY.2015

- **TNF-Alpha Priming Enhances CD4(+) FoxP3(+) Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment**
  Pierini, A., Moffett, C., Schneidawind, D., Baker, J., Nishikii, H., Pan, Y., Alvarez, M., Meyer, E., Negrin, R.
  AMER SOC HEMATOLOGY.2015

- **Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients**
  Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, et al
  AMER SOC HEMATOLOGY.2015

- **Graft-versus-host disease versus graft-versus-leukemia** *HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM*
  Negrin, R. S.
  2015: 225-230

- **Regulatory T Cell Immunotherapy in Immune-Mediated Diseases** *CURRENT STEM CELL REPORTS*
  Pierini, A., Schneidawind, D., Nishikii, H., Negrin, R. S.
  2015; 1 (4): 177–86

- **Graft-versus-host disease versus graft-versus-leukemia** *HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM*
  Negrin, R. S.
  2015: 225–30

- **Regulatory T Cell Immunotherapy in Immune-Mediated Diseases.** *Current stem cell reports*
  Pierini, A., Schneidawind, D., Nishikii, H., Negrin, R. S.
  2015; 1 (4): 177-186

- **Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.** *Haematologica*
  Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., Mattsson, J., Lowsky, R., Negrin, R., Miklos, D. B., Meyer, E.
  2015; 100 (11): 1477-1485

- **MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.** *Blood*
  Buechele, C., Breese, E. H., Schneidawind, D., Lin, C., Jeong, J., Duque-Afonso, J., Wong, S. H., Smith, K. S., Negrin, R. S., Porteus, M., Cleary, M. L.
  2015; 126 (14): 1683-1694

- **Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey** *LEUKEMIA*
  Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, et al
  2015; 29 (10): 2062-2068

- **Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning** *BONE MARROW TRANSPLANTATION*
  Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J. E., JOHNSTON, L. J., Arai, S., Weng, W., Negrin, et al
  2015; 50 (10): 1286-1292

- **UNIPOTENT MEGAKARYOPOIETIC PATHWAY BRIDGING HEMATOPOIETIC STEM CELLS AND MATURE MEGAKARYOCYTES**
  Nishikii, H., Umemoto, T., Goltsev, Y., Matsuzaki, Y., Yamato, M., Nolan, G., Negrin, R., Chiba, S.
  ELSEVIER SCIENCE INC.2015: S85

- **Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.** *Clinical cancer research*
  Filatenkov, A., Baker, J., Mueller, A. M., Kenkel, J., Ahn, G., Dutt, S., Zhang, N., Kohrt, H., Jensen, K., Dejbakhsh-Jones, S., Shizuru, J. A., Negrin, R. N., Engleman, et al
  2015; 21 (16): 3727-3739

- **Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.** *Blood*
  Kim, B., Nishikii, H., Baker, J., Pierini, A., Schneidawind, D., Pan, Y., Beilhack, A., Park, C., Negrin, R. S.
  2015; 126 (4): 546-557

- **Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease** *JOURNAL OF IMMUNOLOGY*
  Pierini, A., Colonna, L., Alvarez, M., Schneidawind, D., Nishikii, H., Baker, J., Pan, Y., Florek, M., Kim, B., Negrin, R. S.
  2015; 195 (1): 347-355

- **Unipotent Megakaryopoietic Pathway Bridging Hematopoietic Stem Cells and Mature Megakaryocytes** *STEM CELLS*
  Nishikii, H., Kanazawa, Y., Umemoto, T., Goltsev, Y., Matsuzaki, Y., Matsushita, K., Yamato, M., Nolan, G. P., Negrin, R., Chiba, S.
  2015; 33 (7): 2196-2207

- **Third-party CD4(+) invariant natural killer T cells protect from murine GVHD lethality** *BLOOD*
  Schneidawind, D., Baker, J., Pierini, A., Buechele, C., Luong, R. H., Meyer, E. H., Negrin, R. S.
  2015; 125 (22): 3491-3500

- **Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.** *Journal of immunology (Baltimore, Md. : 1950)*
  Pierini, A., Colonna, L., Alvarez, M., Schneidawind, D., Nishikii, H., Baker, J., Pan, Y., Florek, M., Kim, B. S., Negrin, R. S.
  2015

- **NK cell reconstitution is improved during allogeneic hematopoietic stem cell transplantation by infusion of NK cell-committed progenitor cells**
  Alvarez, M., Pierini, A., Baker, J., Negrin, R.
  AMER ASSOC IMMUNOLOGISTS.2015

- **ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Logan, A. C., Wang, Z., Alimoghaddam, K., Wong, R. M., Lai, T., Negrin, R. S., Grumet, C., Logan, B. R., Zhang, M., Spellman, S. R., Lee, S. J., Miklos, D. B.
  2015; 21 (4): 746-754

- **Engraftment of Embryonic Stem Cells and Differentiated Progeny by Host Conditioning with Total Lymphoid Irradiation and Regulatory T Cells** *CELL REPORTS*
  Pan, Y., Leveson-Gower, D. B., de Almeida, P. E., Pierini, A., Baker, J., Florek, M., Nishikii, H., Kim, B., Ke, R., Wu, J. C., Negrin, R. S.

2015; 10 (11): 1793-1802

- **Third Party Invariant Natural Killer T Cells Protect from Lethal Graft-Versus-Host Disease through Donor CD4+CD25+FoxP3+Regulatory T Cells**
  Schneidawind, D., Pierini, A., Baker, J., Buechele, C., Luong, R., Meyer, E., Negrin, R.
  ELSEVIER SCIENCE INC.2015: S60
- **Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy**
  Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., Mattsson, J., Lowsky, R., Negrin, R., Miklos, D. B., Meyer, E.
  ELSEVIER SCIENCE INC.2015: S340–S341
- **CD4+FoxP3+Regulatory T Cells Promote B Cell Differentiation and Induce Tolerance to Bone Marrow Grafts**
  Pierini, A., Nishikii, H., Pan, Y., Baker, J., Schneidawind, D., Alvarez, M., Negrin, R.
  ELSEVIER SCIENCE INC.2015: S71–S72
- **Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.** *Bone marrow transplantation*
  Percival, M. M., Medeiros, B. C., Tian, L. n., Robeson, S. n., Laport, G. G., Johnston, L. J., Shizuru, J. A., Miklos, D. B., Arai, S. n., Weng, W. K., Negrin, R. S., Lowsky, R. n.
  2015
- **Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS)**
  Weng, W., Armstrong, R., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Benjamin, J. E., Negrin, R. S., Reddy, S., Million, L., Hoppe, et al
  AMER SOC HEMATOLOGY.2014
- **CD4+FoxP3+Regulatory T Cells Regulate B Cell Differentiation and Induce Tolerance to Bone Marrow Grafts**
  Pierini, A., Nishikii, H., Pan, Y., Baker, J., Leveson-Gower, D. B., Florek, M., Negrin, R.
  AMER SOC HEMATOLOGY.2014
- **Activation of DR3 Signaling Expands Recipient Derived Regulatory T Cells and Enhances Donor Immune Reconstitution Derived from Allogeneic Hematopoietic Stem Cells**
  Nishikii, H., Kim, B., Pierini, A., Baker, J., Schneidawind, D., Pan, Y., Alvarez, M., Negrin, R. S.
  AMER SOC HEMATOLOGY.2014
- **Loss of CD62L Expression in CD4+FoxP3+Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models**
  Florek, M., Schneidawind, D., Baker, J., Pierini, A., Leveson-Gower, D. B., Pan, Y., Negrin, R. S., Meyer, E. H.
  AMER SOC HEMATOLOGY.2014
- **Activation of DR3 Signaling Expands Recipient Derived Regulatory T Cells and Enhances Donor Immune Reconstitution Derived from Allogeneic Hematopoietic Stem Cells**
  Nishikii, H., Kim, B., Pierini, A., Baker, J., Schneidawind, D., Pan, Y., Alvarez, M., Negrin, R. S.
  AMER SOC HEMATOLOGY.2014
- **Loss of CD62L Expression in CD4+FoxP3+Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models**
  Florek, M., Schneidawind, D., Baker, J., Pierini, A., Leveson-Gower, D. B., Pan, Y., Negrin, R. S., Meyer, E. H.
  AMER SOC HEMATOLOGY.2014
- **CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.** *Blood*
  Schneidawind, D., Pierini, A., Alvarez, M., Pan, Y., Baker, J., Buechele, C., Luong, R. H., Meyer, E. H., Negrin, R. S.
  2014; 124 (22): 3320-3328
- **Identification of Orai1 Channel Inhibitors by Using Minimal Functional Domains to Screen Small Molecule Microarrays** *CHEMISTRY & BIOLOGY*
  Sadaghiani, A. M., Lee, S. M., Odegaard, J. I., Leveson-Gower, D. B., McPherson, O. M., Novick, P., Kim, M. R., Koehler, A. N., Negrin, R., Dolmetsch, R. E., Park, C. Y.
  2014; 21 (10): 1278-1292

- **Identification of Orai1 channel inhibitors by using minimal functional domains to screen small molecule microarrays.** *Chemistry & biology*
  Sadaghiani, A. M., Lee, S. M., Odegaard, J. I., Leveson-Gower, D. B., McPherson, O. M., Novick, P., Kim, M. R., Koehler, A. N., Negrin, R., Dolmetsch, R. E., Park, C. Y.
  2014; 21 (10): 1278-1292

- **Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models** *BLOOD*
  Florek, M., Sega, E. I., Leveson-Gower, D. B., Baker, J., Mueller, A. M., Schneidawind, D., Meyer, E., Negrin, R. S.
  2014; 124 (11): 1832-1842

- **Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models.** *Blood*
  Florek, M., Sega, E. I., Leveson-Gower, D. B., Baker, J., Müller, A. M., Schneidawind, D., Meyer, E., Negrin, R. S.
  2014; 124 (11): 1832-1842

- **Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion.** *Radiation research*
  Filatenkov, A., Baker, J., Müller, A. M., Ahn, G., Kohrt, H., Dutt, S., Jensen, K., Dejbakhsh-Jones, S., Negrin, R. S., Shizuru, J. A., Engleman, E. G., Strober, S.
  2014; 182 (2): 163-169

- **Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.** *Biology of blood and marrow transplantation*
  Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.
  2014; 20 (6): 837-843

- **Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.** *Blood*
  Müller, A. M., Poyser, J., Küpper, N. J., Burnett, C., Ko, R. M., Kohrt, H. E., Florek, M., Zhang, P., Negrin, R. S., Shizuru, J. A.
  2014; 123 (18): 2882-2892

- **Role of NKG2D in the induction of mouse natural killer cell exhaustion**
  Alvarez, M., Negrin, R.
  AMER ASSOC IMMUNOLOGISTS.2014

- **Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.** *Blood*
  Müller, A. M., Poyser, J., Küpper, N. J., Burnett, C., Ko, R. M., Kohrt, H. E., Florek, M., Zhang, P., Negrin, R. S., Shizuru, J. A.
  2014; 123 (18): 2882-2892

- **European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation** *BLOOD CANCER JOURNAL*
  Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., Shizuru, J. A., Miklos, D. B., Arai, S., Benjamin, J. E., Weng, W., Negrin, R. S., Lowsky, R.
  2014; 4

- **A killer choice for cancer immunotherapy.** *Immunologic research*
  Schmidt, T. L., Negrin, R. S., Contag, C. H.
  2014; 58 (2-3): 300-306

- **Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Giralt, S., Costa, L., Schriber, J., DiPersio, J., Maziarz, R., McCarty, J., Shaughnessy, P., Snyder, E., Bensinger, W., Copelan, E., Hosing, C., Negrin, R., Petersen, et al
  2014; 20 (3): 295-308

- **CD4(+) Invariant Natural Killer T Cells Protect from Acute Graft-Versus-Host Disease Lethality through a Dramatic Expansion of Donor-Derived CD4(+)FoxP3(+) Regulatory T Cells**
  Schneidawind, D., Pierini, A., Alvarez, M., Pan, Y., Baker, J., Kim, B., Nishikii, H., Buechele, C., Meyer, E., Negrin, R.
  ELSEVIER SCIENCE INC.2014: S23

- **Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience**
  Wudhikarn, K., Lavori, P., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Hoppe, R. T., Benjamin, J., Meyer, E., Negrin, R., Weng, et al

ELSEVIER SCIENCE INC.2014: S164

- **Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation.** *PloS one*
  Sega, E. I., Leveson-Gower, D. B., Florek, M., Schneidawind, D., Luong, R. H., Negrin, R. S.
  2014; 9 (1)
- **CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells** *BLOOD*
  Schneidawind, D., Pierini, A., Alvarez, M., Pan, Y., Baker, J., Buechele, C., Luong, R. H., Meyer, E. H., Negrin, R. S.
  2014
- **Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance.** *Nature communications*
  de Almeida, P. E., Meyer, E. H., Kooreman, N. G., Diecke, S., Dey, D., Sanchez-Freire, V., Hu, S., Ebert, A., Odegaard, J., Mordwinkin, N. M., Brouwer, T. P., Lo, D., Montoro, et al
  2014; 5: 3903-?
- **Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance.** *Nature communications*
  de Almeida, P. E., Meyer, E. H., Kooreman, N. G., Diecke, S., Dey, D., Sanchez-Freire, V., Hu, S., Ebert, A., Odegaard, J., Mordwinkin, N. M., Brouwer, T. P., Lo, D., Montoro, et al
  2014; 5: 3903-?
- **Role of lymphocyte activation gene-3 (lag-3) in conventional and regulatory T cell function in allogeneic transplantation.** *PloS one*
  Sega, E. I., Leveson-Gower, D. B., Florek, M., Schneidawind, D., Luong, R. H., Negrin, R. S.
  2014; 9 (1)
- **Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells.** *Blood*
  Leveson-Gower, D. B., Sega, E. I., Kalesnikoff, J., Florek, M., Pan, Y., Pierini, A., Galli, S. J., Negrin, R. S.
  2013; 122 (22): 3659-3665
- **IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation.** *Biology of blood and marrow transplantation*
  Colonna, L., Florek, M., Leveson-Gower, D. B., Sega, E. I., Baker, J., Smith, A. T., Negrin, R. S.
  2013; 19 (11): 1557-1565
- **Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation.** *Blood*
  Schneidawind, D., Pierini, A., Negrin, R. S.
  2013; 122 (18): 3116-3121
- **Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013)** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D., Weng, W., Negrin, R. S., Carlton, V., Faham, M., Levy, R., Barrett, J.
  2013; 19 (10): 1530
- **A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.** *Blood*
  Meyer, E. H., Hsu, A. R., Liliental, J., Löhr, A., Florek, M., Zehnder, J. L., Strober, S., Lavori, P., Miklos, D. B., Johnson, D. S., Negrin, R. S.
  2013; 121 (24): 4955-4962
- **A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease** *BLOOD*
  Meyer, E. H., Hsu, A. R., Liliental, J., Loehr, A., Florek, M., Zehnder, J. L., Strober, S., Lavori, P., Miklos, D. B., Johnson, D. S., Negrin, R. S.
  2013; 121 (24): 4955-4962
- **Karl Georg Blume, MD In Memoriam** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Forman, S. J., Negrin, R., Chao, N.
  2013; 19 (6): 845–46
- **A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model** *BMC MEDICINE*
  Baeuerlein, C. A., Riedel, S. S., Baker, J., Brede, C., Garrote, A. J., Chopra, M., Ritz, M., Beilhack, G. F., Schulz, S., Zeiser, R., Schlegel, P. G., Einsele, H., Negrin, et al
  2013; 11

- **A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells** *BLOOD*
  Lask, A., Ophir, E., Or-Geva, N., Cohen-Fredarow, A., Afik, R., Eidelstein, Y., Reich-Zeliger, S., Nathansohn, B., Edinger, M., Negrin, R. S., Hagin, D., Reisner, Y.
  2013; 121 (15): 3033-3040

- **Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells** *BLOOD*
  Ophir, E., Or-Geva, N., Gurevich, I., Tal, O., Eidelstein, Y., Shezen, E., Margalit, R., Lask, A., Shakhar, G., Hagin, D., Bachar-Lustig, E., Reich-Zeliger, S., Beilhack, et al
  2013; 121 (7): 1220-1228

- **The Expansion of Gastrointestinal-Associated alpha beta T Cell Clones in Peripheral Blood Associates with Severe Steroid Refractory GVHD** *BMT Tandem Meetings*
  Meyer, E. H., Liliental, J. A., Florek, M., Lohr, A., Hsu, A., Johnson, D., Lavori, P., Zehnder, J. L., Miklos, D. B., Strober, S., Negrin, R.
  ELSEVIER SCIENCE INC.2013: S334–S335

- **Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation** *BMT Tandem Meetings*
  Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J., Johnston, L., Arai, S., Weng, W., Negrin, R., Strober, et al
  ELSEVIER SCIENCE INC.2013: S154–S155

- **TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN** *BMT Tandem Meetings*
  Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R., Lowsky, R.
  ELSEVIER SCIENCE INC.2013: S113–S114

- **A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model.** *BMC medicine*
  Bäuerlein, C. A., Riedel, S. S., Baker, J., Brede, C., Garrote, A. J., Chopra, M., Ritz, M., Beilhack, G. F., Schulz, S., Zeiser, R., Schlegel, P. G., Einsele, H., Negrin, et al
  2013; 11: 134-?

- **Cancer Vaccines and T Cell Therapy** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., Weng, W., Negrin, R. S., Carlton, V., Faham, M., Levy, R., Barrett, J.
  2013; 19 (1): S97-S101

- **Mapping immune processes in intact tissues at cellular resolution.** *journal of clinical investigation*
  Brede, C., Friedrich, M., Jordán-Garrote, A., Riedel, S. S., Bäuerlein, C. A., Heinze, K. G., Bopp, T., Schulz, S., Mottok, A., Kiesel, C., Mattenheimer, K., Ritz, M., von Krosigk, et al
  2012; 122 (12): 4439-4446

- **Mapping immune processes in intact tissues at cellular resolution** *JOURNAL OF CLINICAL INVESTIGATION*
  Brede, C., Friedrich, M., Jordan-Garrote, A., Riedel, S. S., Baeuerlein, C. A., Heinze, K. G., Bopp, T., Schulz, S., Mottok, A., Kiesel, C., Mattenheimer, K., Ritz, M., von Krosigk, et al
  2012; 122 (12): 4439-4446

- **Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
  Benjamin, J., Chhabra, S., Kohrt, H. E., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.
  AMER SOC HEMATOLOGY.2012

- **The Expansion of Gastrointestinal-associated alpha beta T Cell Clones in Peripheral Blood Over Time Is a Disease Feature of Severe Acute Graft-Versus-Host Disease** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
  Meyer, E. H., Liliental, J., Florek, M., Loehr, A., Hsu, A., Johnson, D. S., Miklos, D. B., Zehnder, J. L., Negrin, R. S.
  AMER SOC HEMATOLOGY.2012

- **Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence** *BLOOD*
  Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., Shizuru, J. A., Johnston, L. J., Laport, G. G., Weng, W., Benjamin, J. E., Schaenman, J., Brown, et al

2012; 119 (25): 6145-6154

- **Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells** *BLOOD*
  Gill, S., Vasey, A. E., De Souza, A., Baker, J., Smith, A. T., Kohrt, H. E., Florek, M., Gibbs, K. D., Tate, K., Ritchie, D. S., Negrin, R. S.
  2012; 119 (24): 5758-5768

- **Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Mueller, A. M., Shashidhar, S., Kuepper, N. J., Kohrt, H. E., Florek, M., Negrin, R. S., Brown, J. M., Shizuru, J. A.
  2012; 109 (15): 5820-5825

- **Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
  Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Sheehan, K., Lavori, P., Negrin, et al
  2012; 47 (4): 581-588

- **Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma** *BONE MARROW TRANSPLANTATION*
  Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., Miklos, D. B., Arai, S., Weng, W., Laport, G. G., Stockerl-Goldstein, K.
  2012; 47 (4): 516-521

- **Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow** *BLOOD*
  Mielcarek, M., Storer, B., Martin, P. J., Forman, S. J., Negrin, R. S., Flowers, M. E., Inamoto, Y., Chauncey, T. R., Storb, R., Appelbaum, F. R., Bensinger, W. I.
  2012; 119 (11): 2675-2678

- **Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Mueller, A. M., Kohrt, H. E., Cha, S., Laport, G., Klein, J., Guardino, A. E., Johnston, L. J., Stockerl-Goldstein, K. E., Hanania, E., Juttner, C., Blume, K. G., Negrin, R. S., Weissman, et al
  2012; 18 (1): 125-133

- **Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Guerrero, A., Riddell, S. R., Storek, J., Stevens-Ayers, T., Storer, B., Zaia, J. A., Forman, S., Negrin, R. S., Chauncey, T., Bensinger, W., Boeckh, M.
  2012; 18 (1): 66-75

- **Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
  Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J., Klinger, M., Faham, M., Advani, R., Kohrt, H. E., Alizadeh, A. A., Negrin, R. S., Weng, W., Sheehan, et al
  AMER SOC HEMATOLOGY.2011: 1323–23

- **Natural Killer Cell Adoptive Immunotherapy Is Hampered by A Rapid Development of NK Cell Dysfunction Characterized by Loss of Effector Mechanisms and Downregulation of the Transcription Factors T-Bet and Eomesodermin; Definition and Possible Mechanism of NK Cell Exhaustion** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
  Gill, S. I., Vasey, A. E., Baker, J. B., Smith, A., Kohrt, H. E., Florek, M., Ritchie, D., Negrin, R. S.
  AMER SOC HEMATOLOGY.2011: 457–57

- **The Inhibitory Receptor LAG-3 Is Not Essential for Regulatory T Cells Function but Influences Donor T Cell Potency in Acute Graft-Versus-Host-Disease**
  Sega, E. I., Leveson-Gower, D. B., Florek, M., Negrin, R. S.
  AMER SOC HEMATOLOGY.2011: 829

- **Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes**
  Mielcarek, M., Storer, B., Martin, P. J., Negrin, R. S., Forman, S. J., Flowers, M. E. D., Inamoto, Y., Chauncey, T., Storb, R., Appelbaum, F. R., Bensinger, W. I.

AMER SOC HEMATOLOGY.2011: 149

- **IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease Following Bone Marrow Transplantation**
  Colonna, L., Florek, M., Leveson-Gower, D. B., Sega, E. I., Zeiser, R., Buess, M., Negrin, R. S.
  AMER SOC HEMATOLOGY.2011: 1724

- **Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., Johnston, L. J., Shizuru, J. A., Miklos, D., Arai, S., Benjamin, J. E., Weng, W., Negrin, et al
  2011; 17 (11): 1679-1687

- **Role of regulatory T cell populations in controlling graft vs host disease** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*
  Negrin, R. S.
  2011; 24 (3): 453-457

- **Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4(+)CD25(+)Foxp3(+) regulatory T cells** *BLOOD*
  Shin, H., Baker, J., Leveson-Gower, D. B., Smith, A. T., Sega, E. I., Negrin, R. S.
  2011; 118 (8): 2342-2350

- **Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Tomblyn, M. R., Ewell, M., Bredeson, C., Kahl, B. S., Goodman, S. A., Horowitz, M. M., Vose, J. M., Negrin, R. S., Laport, G. G.
  2011; 17 (7): 1051-1057

- **Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism** *BLOOD*
  Leveson-Gower, D. B., Olson, J. A., Sega, E. I., Luong, R. H., Baker, J., Zeiser, R., Negrin, R. S.
  2011; 117 (11): 3220-3229

- **CD8(+)CD44(hi) but not CD4(+)CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD** *BLOOD*
  Dutt, S., Baker, J., Kohrt, H. E., Kambham, N., Sanyal, M., Negrin, R. S., Strober, S.
  2011; 117 (11): 3230-3239

- **Short-Term Immunosuppression Promotes Engraftment of Embryonic and Induced Pluripotent Stem Cells** *CELL STEM CELL*
  Pearl, J. I., Lee, A. S., Leveson-Gower, D. B., Sun, N., Ghosh, Z., Lan, F., Ransohoff, J., Negrin, R. S., Davis, M. M., Wu, J. C.
  2011; 8 (3): 309-317

- **Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY** *BONE MARROW TRANSPLANTATION*
  Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Blume, K., Negrin, R., Johnston, L.
  2011; 46 (2): 192-199

- **KINETICS OF MURINE GVHD INDUCTION ACROSS MINOR AND MAJOR HISTOCOMPATIBILITY BARRIERS** *Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem*
  Vasey, A. E., Baker, J. B., Leveson-Gower, D. B., Negrin, R. S.
  ELSEVIER SCIENCE INC.2011: S340–S340

- **SINGLE DOSE ADMINISTRATION OF ECP TREATED CELLS PRIOR TO TRANSPLANTATION SIGNIFICANTLY INCREASES SURVIVAL IN A MHC-MISMATCHED MODEL OF ACUTE GVHD** *Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem*
  Florek, M., Sega, E. I., Leveson-Gower, D. B., Gill, S., Mueller, A. M., Negrin, R. S.
  ELSEVIER SCIENCE INC.2011: S337–S338

- **LONG-TERM FOLLOW-UP OF METASTATIC BREAST CANCER PATIENTS RECEIVING HIGHLY PURIFIED AUTOLOGOUS CD34+THY-1+HEMATOPOIETIC STEM CELLS AFTER HIGH-DOSE CHEMOTHERAPY** *Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem*
  Mueller, A. M., Kohrt, H. E., Laport, G. G., Negrin, R. S., Cha, S., Weissman, I. L., Shizuru, J. A.
  ELSEVIER SCIENCE INC.2011: S198–S198

- **Natural and Expanded CD4(+) CD25(+) Regulatory T Cells in Bone Marrow Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Colonna, L., Sega, E. I., Negrin, R. S.

2011; 17 (1): S58-S62

- **CXCL12 Mediates Immunosuppression in the Lymphoma Microenvironment after Allogeneic Transplantation of Hematopoietic Cells** *CANCER RESEARCH*
  Duerr, C., Pfeifer, D., Claus, R., Schmitt-Graeff, A., Gerlach, U. V., Graeser, R., Krueger, S., Gerbitz, A., Negrin, R. S., Finke, J., Zeiser, R.
  2010; 70 (24): 10170-10181

- **Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells** *CANCER RESEARCH*
  Contag, C. H., Sikorski, R., Negrin, R. S., Schmidt, T., Fan, A. C., Bachireddy, P., Felsher, D. W., Thorne, S. H.
  2010; 70 (23): 9837-9845

- **Definition of a Diagnostic Window Prior to the Onset of Clinically Apparent Acute Graft-Versus-Host Disease** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
  Baeuerlein, C. A., Riedel, S. S., Christian, B., Garrote, A. J., Birner, A., Kiesel, C., Ritz, M., Schulz, S., Grether, M., Beilhack, G. F., Negrin, R., Einsele, H., Beilhack, et al
  AMER SOC HEMATOLOGY.2010: 1536–37

- **Mast Cells Reduce Gvhd Severity In Allogeneic Transplantation by Reducing the Proliferation of Conventional T Cells**
  Leveson-Gower, D. B., Sega, E. I., Kalesnikoff, J., Florek, M., Galli, S. J., Negrin, R.
  AMER SOC HEMATOLOGY.2010: 112

- **Similarities In the Initial Events of Murine Gvhd Across Minor. as Compared to Major, Histocompatibility Barriers** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
  Vasey, A. E., Baker, J. B., Leyeson-Gower, D. B., Negrin, R.
  AMER SOC HEMATOLOGY.2010: 1537–38

- **Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
  Krishnan, A., Pasquini, M. C., Ewell, M., Stadtmauer, E. A., Alyea, E. P., Antin, J. H., Comenzo, R. L., Goodman, S., Hari, P., Negrin, R., Qazilbash, M. H., Rowley, S. D., Sahebi, et al
  AMER SOC HEMATOLOGY.2010: 24–25

- **Tandem Autologous Stem Cell Transplants (auto-auto) With or without Maintenance Therapy Versus Single Autologous Transplant Followed by HLA-Matched Sibling Non- Myeloablative Allogeneic Stem Cell Transplant (auto-allo) for Patients (pts) with High Risk (HR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
  Stadtmauer, E. A., Krishnan, A., Pasquini, M. C., Ewell, M., Alyea, E. P., Antin, J. H., Castro-Malaspina, H., Kassim, A. A., Negrin, R., Qazilbash, M. H., Rizzo, J. D., Rowley, S. D., Sahebi, et al
  AMER SOC HEMATOLOGY.2010: 233–34

- **Ex Vivo Generated Donor Central Memory CD8 T Cells, Previously Shown to Enhance Engraftment of Allogeneic Bone Marrow, Also Exhibit Significant GVL Activity without Causing Gvhd In An In Vivo b Cell Lymphoma Model**
  Lask, A., Ophir, E., Or-Geva, N., Cohen, A., Afik, R., Eidelstein, Y., Negrin, R., Nagler, A., Berrebi, A., Hagin, D., Reisner, Y.
  AMER SOC HEMATOLOGY.2010: 189–90

- **Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Weng, W., Lavori, P. W., Blume, K. G., Negrin, R. S., Horning, et al
  2010; 16 (8): 1145-1154

- **CD11B+CD11C+DENDRITIC CELLS INTERACT WITH ALLOREACTIVE T CELLS IN THE INTESTINAL MUCOSA IN ACUTE GRAFT-VERSUS-HOST DISEASE** *15th Annual Meeting of the European-Hematology-Association*
  Garrote, A. L., Brede, C., Baeuerlein, C., Riedel, S., Kiesel, C., Grether, M., Mattenheimer, K., Ritz, M., Baker, J., Negrin, R., Einsele, H., Beilhack, A., Schulz, et al
  FERRATA STORTI FOUNDATION.2010: 480–480

- **DIFFERENCES IN ALLOREACTIVE T CELL MIGRATION IN MHC MATCHED VERSUS MHC MISMATCHED HCT ARE CAUSED BY WAVES OF T CELL EXPANSION** *15th Annual Meeting of the European-Hematology-Association*
  Baeuerlein, C., Riedel, S., Brede, C., Garrote, A. L., Kiesel, C., Ritz, M., Schulz, S., Grether, M., Beilhack, G., Negrin, R., Einsele, H., Beilhack, A.

FERRATA STORTI FOUNDATION.2010: 479–479

- **NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects** *BLOOD*
  Olson, J. A., Leveson-Gower, D. B., Gill, S., Baker, J., Beilhack, A., Negrin, R. S.
  2010; 115 (21): 4293-4301

- **Biology and clinical effects of natural killer cells in allogeneic transplantation** *CURRENT OPINION IN ONCOLOGY*
  Benjamin, J. E., Gill, S., Negrin, R. S.
  2010; 22 (2): 130-137

- **CD107 surface mobilization of peripheral blood T-cells to predict acute graft-versus-host disease** *36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting*
  Baeuerlin, C. A., Brede, C., Riedel, S. S., Garrote, A. J., Kiesel, C., Ritz, M., Schulz, S., Beilhack, G. F., Stuge, T. B., Negrin, R. S., Einsele, H., Beilhack, A.
  NATURE PUBLISHING GROUP.2010: S117–S117

- **Simultaneous blockade of several endothelial ligands is required to prevent alloreactive T-cell trafficking to target tissues** *36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting*
  Beilhack, A., Baker, J., Riedel, S., Brede, C., Baeuerlein, C. A., Jordan-Garrote, A. L., Kiesel, C., Monteforte, R., Ritz, M., Mattenheimer, K., Grether, M., Beilhack, G. F., Einsele, et al
  NATURE PUBLISHING GROUP.2010: S15–S15

- **Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure** *BONE MARROW TRANSPLANTATION*
  Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., Sheehan, K., Shizuru, J. A., JOHNSTON, L. J., Negrin, R. S., Lowsky, R., Laport, G. G.
  2010; 45 (2): 303-309

- **Immunoglobulin G Fc Receptor Fc gamma RIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
  Weng, W., Negrin, R. S., Lavori, P., Horning, S. J.
  2010; 28 (2): 279-284

- **Memory Phenotype CD8+T Cells Are Superior to Naive CD8+T Cells in Separating Graft Anti-Tumor Activity From Gvhd After Bone Marrow Transplantation; Application to DLI.**
  Dutt, S., Baker, J., Kambham, N., Kohrt, H. E., Negrin, R., Strober, S.
  AMER SOC HEMATOLOGY.2009: 967

- **Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal Cells** *STEM CELLS*
  Zangi, L., Margalit, R., Reich-Zeliger, S., Bachar-Lustig, E., Beilhack, A., Negrin, R., Reisner, Y.
  2009; 27 (11): 2865-2874

- **Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
  Gyurkocza, B., Cao, T. M., Storb, R. F., Lange, T., Leisenring, W., Franke, G. N., Sorror, M., Hoppe, R., Maloney, D. G., Negrin, R. S., Shizuru, J. A., Sandmaier, B. M.
  ELSEVIER SCIENCE INC.2009: 1314–22

- **Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation** *JOURNAL OF IMMUNOLOGY*
  Olson, J. A., Zeiser, R., Beilhack, A., Goldman, J. J., Negrin, R. S.
  2009; 183 (5): 3219-3228

- **TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors** *BLOOD*
  Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., Johnston, L. J., Arai, S., Weng, W., Hoppe, R. T., Lavori, P. W., Blume, K. G., Negrin, et al
  2009; 114 (5): 1099-1109

- **Natural Killer Cells in Allogeneic Transplantation: Effect on Engraftment, Graft- versus-Tumor, and Graft-versus-Host Responses** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*

Gill, S., Olson, J. A., Negrin, R. S.
2009; 15 (7): 765-776

- **Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML** *BLOOD*
  Zeng, Z., Shi, Y. X., Samudio, I. J., Wang, R., Ling, X., Frolova, O., Levis, M., Rubin, J. B., Negrin, R. R., Estey, E. H., Konoplev, S., Andreeff, M., Konopleva, et al
  2009; 113 (24): 6215-6224

- **Regulation of different inflammatory diseases by impacting the mevalonate pathway** *IMMUNOLOGY*
  Zeiser, R., Maas, K., Youssef, S., Duerr, C., Steinman, L., Negrin, R. S.
  2009; 127 (1): 18-25

- **Cytotoxicity of human CD8+T-cells and NK-cells is suppressed by an alternative NKG2D splice variant**
  Karimi, M. A., Bachmann, M. H., Cao, T. M., Wang, C., Kim, E., Watts, T. H., Negrin, R. S., Zhang, L.
  AMER ASSOC IMMUNOLOGISTS.2009

- **Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Abrahamsson, A. E., Geron, I., Gotlib, J., Dao, K. T., Barroga, C. F., Newton, I. G., Giles, F. J., Durocher, J., Creusot, R. S., Karimi, M., Jones, C., Zehnder, J. L., Keating, et al
  2009; 106 (10): 3925-3929

- **Follicular lymphoma B cells induce the conversion of conventional CD4(+) T cells to T-regulatory cells** *INTERNATIONAL JOURNAL OF CANCER*
  Ai, W. Z., Hou, L., Zeiser, R., Czerwinski, D., Negrin, R. S., Levy, R.
  2009; 124 (1): 239-244

- **Functional Comparison of Freshly Isolated and Ex-Vivo Expanded CD4(+)CD25(+)Foxp3(+) Regulatory T Cells in Suppressing Murine Acute GvHD**
  Sega, E. I., Leveson-Gower, D., Nguyen, V. H., Negrin, R.
  AMER SOC HEMATOLOGY.2008: 302

- **Use of R-spondin1, An Intestinotrophic Mitogen, in the Treatment of Murine Graft-Versus-Host Disease** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
  Zambricki, E. A., Ootani, A., Mancuso, M. R., Zeiser, R., Kuo, C. J., Negrin, R. S.
  AMER SOC HEMATOLOGY.2008: 1206–

- **NK Cells Suppress Gvhd by Directly Inhibiting Activated Alloreactive T Cells through An NKG2D-Mediated Mechanism** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
  Olson, J. A., Leveson-Gower, D. B., Baker, J., Bcilhack, A., Negrin, R.
  AMER SOC HEMATOLOGY.2008: 30–30

- **Mesenchymal Stem Cells (MSC) Are Not Intrinsically Immune Privileged: Direct Demonstration in TCR Transgenic Mice and by Imaging of Allogeneic Luciferase plus MSC in Immune Competent Vs Immune Deficient Mice**
  Zangi, L., Beilhack, A., Negrin, R., Margalit, R., Reisner, Y.
  AMER SOC HEMATOLOGY.2008: 205–6

- **Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation** *JOURNAL OF IMMUNOLOGY*
  Reichardt, W., Duerr, C., von Elverfeldt, D., Juettner, E., Gerlach, U. V., Yamada, M., Smith, B., Negrin, R. S., Zeiser, R.
  2008; 181 (7): 4770-4779

- **In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity** *BLOOD*
  Nishimura, R., Baker, J., Beilhack, A., Zeiser, R., Olson, J. A., Sega, E. I., Karimi, M., Negrin, R. S.
  2008; 112 (6): 2563-2574

- **Plasmacytoid dendritic cells take up opsonized antigen leading to CD4(+) and CD8(+) T cell activation in vivo** *JOURNAL OF IMMUNOLOGY*
  Bjorck, P., Beilhack, A., Herman, E. I., Negrin, R. S., Engleman, E. G.
  2008; 181 (6): 3811-3817

- **Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen** *BLOOD*
  Laport, G. G., Alvarnas, J. C., Palmer, J. M., Snyder, D. S., Slovak, M. L., Cherry, A. M., Wong, R. M., Negrin, R. S., Blume, K. G., Forman, S. J.
  2008; 112 (3): 903-909

- **Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Chen, A. I., McMillan, A., Neprin, R. S., Horning, S. J., Laport, G. G.
  2008; 14 (7): 741-747

- **Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs** *BLOOD*
  Beilhack, A., Schulz, S., Baker, J., Beilhack, G. F., Nishimura, R., Baker, E. M., Landan, G., Herman, E. I., Butcher, E. C., Contag, C. H., Negrin, R. S.
  2008; 111 (5): 2919-2928

- **Interleukin-2 receptor downstream events in regulatory T cells - Implications for the choice of immunosuppressive drug therapy** *CELL CYCLE*
  Zeiser, R., Negrin, R. S.
  2008; 7 (4): 458-462

- **The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation** *BLOOD*
  Nguyen, V. H., Shashidhar, S., Chang, D. S., Ho, L., Kambham, N., Bachmann, M., Brown, J. M., Negrin, R. S.
  2008; 111 (2): 945-953

- **Differential impact of mammalian target of rapamycin inhibition on CD4(+)CD25(+)Foxp3(+) regulatory T cells compared with conventional CD4(+) T cells** *BLOOD*
  Zeiser, R., Leveson-Gower, D. B., Zambricki, E. A., Kambham, N., Beilhack, A., Loh, J., Hou, J., Negrin, R. S.
  2008; 111 (1): 453-462

- **Mouse models of bone marrow transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Reddy, P., Negrin, R., Hill, G. R.
  2008; 14 (1): 129-135

- **Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity** *BLOOD*
  Zeiser, R., Youssef, S., Baker, J., Kambham, N., Steinman, L., Negrin, R. S.
  2007; 110 (13): 4588-4598

- **Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Zeiser, R., Zambricki, E. A., Leveson-Gower, D., Kambham, N., Beilhack, A., Negrin, R. S.
  2007; 13 (12): 1427-1438

- **Missplicing of glycogen synthase kinase 3 beta: A potential mechanism of blast crisis chronic myeloid leukemia stem cell generation** *49th Annual Meeting of the American-Society-of-Hematology*
  Abrahamsson, A., Geron, I., Gotlib, J., Dao, K., Giles, F., Newton, I., Kavaterchik, E., Durocher, J., Creusot, R., Karimi, M., Jones, C., Zehnder, J., Keating, et al
  AMER SOC HEMATOLOGY.2007: 238A–239A

- **Long term results of autologous hematopoietic cell transplantation (AHCT) for peripheral T cell lymphoma: The Stanford experience**
  Chen, A. I., McMillan, A., Negrin, R. S., Horning, S. J., Laport, G. G.
  AMER SOC HEMATOLOGY.2007: 566A

- **NK cells induce alloreactive donor T cell apoptosis and decrease proliferation in GVHD induction**
  Olson, J. A., Leveson-Gower, D. B., Beilhack, A., Negrin, R. S.
  AMER SOC HEMATOLOGY.2007: 643A

- **Differential impact of host derived interleukin-18 on regulatory and conventional T cell expansion following murine allogeneic hematopoietic cell transplantation**
  Zeiser, R., Zambricki, E. A., Gower, D., Beilhack, A., Kambham, N., Negrin, R. S.
  AMER SOC HEMATOLOGY.2007: 958A

- **A novel technique for the enrichment of primary ovarian cancer cells** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
  Chan, J. K., Hamilton, C. A., Anderson, E. M., Cheung, M. K., Baker, J., Husain, A., Teng, N. N., Kong, C. S., Negrin, R. S.
  2007; 197 (5)

- **Blood and marrow transplant clinical trials network state of the science symposium 2007** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Ferrara, J. L., Anasetti, C., Stadtmauer, E., Antin, J., Wingard, J., Lee, S., Levine, J., Schultz, K., Appelbaum, F., Negrin, R., Giralt, S., Bredeson, C., Heslop, et al
  2007; 13 (11): 1268-1285

- **CD101 surface expression discriminates potency among murine FoxP3(+) regulatory T cells** *JOURNAL OF IMMUNOLOGY*
  Fernandez, I., Zeiser, R., Karsunky, H., Kambham, N., Beilhack, A., Soderstrom, K., Negrin, R. S., Engleman, E.
  2007; 179 (5): 2808-2814

- **CD101 surface expression discriminates potency among murine FoxP3+regulatory T cells**
  Fernandez, I., Zeiser, R., Karsunky, H., Kambham, N., Beilhack, A., Sodestrom, K., Negrin, R., Engleman, E.
  AMER ASSOC IMMUNOLOGISTS.2007

- **In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation** *BLOOD*
  Nguyen, V. H., Zeiser, R., daSilva, D. L., Chang, D. S., Beilhack, A., Contag, C. H., Negrin, R. S.
  2007; 109 (6): 2649-2656

- **Early CD30 signaling is critical for adoptively transferred CD4(+)CD25(+) regulatory T cells in prevention of acute graft-versus-host disease** *BLOOD*
  Zeiser, R., Nguyen, V. H., Hou, J., Beilhack, A., Zambricki, E., Buess, M., Contag, C. H., Negrin, R. S.
  2007; 109 (5): 2225-2233

- **The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia** *BLOOD*
  Oehler, V. G., Gooley, T., Snyder, D. S., Johnston, L., Lin, A., Cummings, C. C., Chu, S., Bhatia, R., Forman, S. J., Negrin, R. S., Appelbaum, F. R., Radich, J. P.
  2007; 109 (4): 1782-1789

- **Promise and challenges of human regulatory T cells in the clinic** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Negrin, R. S., Hou, J.
  2007; 13 (1): 12-16

- **Alloreactive T-cell trafficking after hematopoietic stem cell transplantation.** *Journal of stem cells & regenerative medicine*
  Beilhack, A., Schulz, S., Baker, J., Beilhack, G., Herman, E., Baker, E., Landan, G., Nishimura, R., Butcher, E., Contag, C., Negrin, R.
  2007; 2 (1): 107-?

- **Alloreactive T-cell trafficking after hematopoietic stem cell transplantation.** *Journal of stem cells & regenerative medicine*
  Beilhack, A., Schulz, S., Baker, J., Beilhack, G., Herman, E., Baker, E., Landan, G., Nishimura, R., Butcher, E., Contag, C., Negrin, R.
  2007; 2 (1): 17-?

- **Allogeneic cytokine-induced killer cells traffick to GVHD target tissue but cause less GVHD, while retaining tumor cytotoxicity and facilitating bone marrow engraftment.** *48th Annual Meeting of the American-Society-of-Hematology*
  Nishimura, R., Baker, J., Beilhack, A., Negrin, R.
  AMER SOC HEMATOLOGY.2006: 904A–904A

- **CD4+CD25+ Regulatory T cells enhance immune reconstitution following allogeneic hematopoietic cell transplantation by protecting thymic and lymphoid compartments from graft-versus-host disease damage without impacting T cell repertoire development.** *48th Annual Meeting of the American-Society-of-Hematology*
  Nguyen, V. H., Chang, D., Shashidhar, S., Bachmann, M., Contag, C. H., Brown, J. M., Negrin, R. S.
  AMER SOC HEMATOLOGY.2006: 25A–25A

- **Impact of mTOR inhibition on FoxP3+ regulatory T cells as compared to conventional T cells after allogeneic bone marrow transplantation.**
  Zeiser, R., Leveson-Gower, D. B., Zambricki, E. A., hou, J., Negrin, R.
  AMER SOC HEMATOLOGY.2006: 136A–137A

- **Tissue-specific homing of natural killer cells in allogeneic bone marrow transplantation.**

Olson, J. A., Zeiser, R., Beilhack, A., Negrin, R. S.
AMER SOC HEMATOLOGY.2006: 276A

- **Allogeneic environment and tissue damage provide critical stimuli for regulatory T cell expansion and survival in vivo after hematopoietic cell transplantation.** *48th Annual Meeting of the American-Society-of-Hematology*
  Nguyen, V. H., Chang, D., Negrin, R. S.
  AMER SOC HEMATOLOGY.2006: 491A–491A

- **Membranous glomerulonephritis and nephrotic syndrome as a late manifestation of chronic graft-versus-host reaction following allogeneic transplantation for hematologic malignancy.**
  Ahmad, B., Stehr, B., Johnston, L., Smith, E., Nademanee, A. P., Parker, P., Negrin, R., Forman, S. J.
  AMER SOC HEMATOLOGY.2006: 819A–820A

- **Type IIHMG-CoA reductase inhibitors (Statins) provide acute-graft-versus-host disease protection by Th-2 cytokine induction while sparing graft-versus-leukemia activity.** *48th Annual Meeting of the American-Society-of-Hematology*
  Zeiser, R., Youssef, S., Baker, J., Steinman, L., Negrin, R.
  AMER SOC HEMATOLOGY.2006: 60A–60A

- **Selective expansion of human regulatory (CD4+CD25+CD12 7LowFOXP3+) cells to high purity by inhibiting expansion of CD4+CD25+CD127HighFOXP3-Conventional T cells with rapamycin.**
  Hou, J., Zambricki, E., Zeiser, R., Negrin, R. S.
  AMER SOC HEMATOLOGY.2006: 902A–903A

- **Role of naturally arising regulatory T cells in hematopoietic cell transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Nguyen, V. H., Zeiser, R., Negrin, R. S.
  2006; 12 (10): 995-1009

- **High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Shizuru, J. A., Blume, K. G., Negrin, R. S., Stockerl-Goldstein, K. E.
  2006; 12 (7): 703-711

- **Inhibition of CD4(+)CD25(+) regulatory T-cell function by calcineurin-dependent interleukin-2 production** *BLOOD*
  Zeiser, R., Nguyen, V. H., Beilhack, A., Buess, M., Schulz, S., Baker, J., Contag, C. H., Negrin, R. S.
  2006; 108 (1): 390-399

- **In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease.** *Nature reviews. Immunology*
  Negrin, R. S., Contag, C. H.
  2006; 6 (6): 484-490

- **Innovation - In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease** *NATURE REVIEWS IMMUNOLOGY*
  Negrin, R. S., Contag, C. H.
  2006; 6 (6): 484-U2

- **Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation.** *Current stem cell research & therapy*
  Zeiser, R., Beilhack, A., Negrin, R. S.
  2006; 1 (2): 203-212

- **Deletion mutation in human NKG2D ligand effects tumors resistance to T cells mediated cytotoxicity** *Annual Meeting of the American-Association-of-Immunologists*
  Karimi, M. A., Su, L., Chan, J. K., Negrin, R. S.
  AMER ASSOC IMMUNOLOGISTS.2006: S264–S264

- **Synergistic antitumor effects of immune cell-viral biotherapy** *SCIENCE*
  Thorne, S. H., Negrin, R. S., Contag, C. H.
  2006; 311 (5768): 1780-1784

- **Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study** *CLINICAL CANCER RESEARCH*

Chan, J. K., Hamilton, C. A., Cheung, M. K., Karimi, M., Baker, J., Gall, J. M., Schulz, S., Thorne, S. H., Teng, N. N., Contag, C. H., Lum, L. G., Negrin, R. S.
2006; 12 (6): 1859-1867

- **The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab** *CYTOTHERAPY*
  Kornacker, M., Verneris, M. R., Kornacker, B., Ganten, T. M., Scheffold, C., Negrin, R. S.
  2006; 8 (1): 13-23
- **Total lymphoid irradiation and transplantation tolerance** *CURRENT OPINION IN ORGAN TRANSPLANTATION*
  Lowsky, R., Negrin, R. S.
  2006; 11 (1): 54-61
- **Deletion in H-NKG2D ligand effects tumors resistance to T-cells mediated cytotoxicity.** *6th Annual Meeting of the Federation-of-Clinical-Immunology-Societies*
  Karimi, M., Su, L., Chan, J., Negrin, R.
  ACADEMIC PRESS INC ELSEVIER SCIENCE.2006: S93–S94
- **Protective conditioning for acute graft-versus-host disease - Reply** *NEW ENGLAND JOURNAL OF MEDICINE*
  Lowsky, R., Negrin, R. S., Strober, S.
  2005; 353 (25): 2718-2718
- **Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8(+) T cells and NK cells** *JOURNAL OF IMMUNOLOGY*
  Karimi, M., Cao, T. M., Baker, J. A., Verneris, M. R., Soares, L., Negrin, R. S.
  2005; 175 (12): 7819-7828
- **Immunotherapy of primary ovarian cancer using autologous cytokine induced killer cells retargeted with bispecific antibodies: A preclinical study.** *47th Annual Meeting of the American-Society-of-Hematology*
  Chan, J. K., Hamilton, C. A., Cheung, M. K., Karimi, M., Baker, J., Gall, J. M., Lum, L. G., Schulz, S., Thorne, S. H., Teng, N. N., Contag, C. H., Negrin, R. S.
  AMER SOC HEMATOLOGY.2005: 669A–670A
- **CD62L and CD31 matching are independent risk factors for survival after bone marrow transplantation.**
  Yu, W., Hiraki, D., Sequiera, J., Negrin, R., Grumet, F. C., Lowsky, R.
  AMER SOC HEMATOLOGY.2005: 411A
- **Trafficking and expansion of NK cells in murine models of bone marrow transplantation.**
  Olson, J. A., Negrin, R.
  AMER SOC HEMATOLOGY.2005: 672A
- **Bioluminescent imaging of human leukemic stem cell engraftment.** *47th Annual Meeting of the American-Society-of-Hematology*
  Jamieson, C., Karimi, M., Creusot, R., Negrin, R., Gotlib, J., Chao, M., Jones, C., Keating, A., Fathman, C. G., Zehnder, J., Weissman, I. L.
  AMER SOC HEMATOLOGY.2005: 205A–205A
- **Isolation and characterization of human CD4+CD25+T regulatory cells for early phase clinical trials in hematopoietic cell transplantation.** *47th Annual Meeting of the American-Society-of-Hematology*
  Hou, J. Z., Baker, J., Sheehan, K., Negrin, R. S.
  AMER SOC HEMATOLOGY.2005: 368A–368A
- **Prevention of acute graft-versus-host disease by CD4+ CD25+ regulatory T cells is dependent on the CD30/CD153 pathway.** *47th Annual Meeting of the American-Society-of-Hematology*
  Zeiser, R., Nguyen, V., Buess, M., Karimi, M., Bjorck, P., Baker, J., Negrin, R. S.
  AMER SOC HEMATOLOGY.2005: 378A–378A
- **CD62L and CD31 matching are independent risk factors for survival after bone marrow transplantation.**
  Yu, W., Hiraki, D., Sequiera, J., Negrin, R., Grumet, F. C., Lowsky, R.
  AMER SOC HEMATOLOGY.2005: 411A
- **Trafficking and expansion of NK cells in murine models of bone marrow transplantation.**
  Olson, J. A., Negrin, R.
  AMER SOC HEMATOLOGY.2005: 672A

- **Bioluminescent imaging of human leukemic stem cell engraftment.** *47th Annual Meeting of the American-Society-of-Hematology*
  Jamieson, C., Karimi, M., Creusot, R., Negrin, R., Gotlib, J., Chao, M., Jones, C., Keating, A., Fathman, C. G., Zehnder, J., Weissman, I. L.
  AMER SOC HEMATOLOGY.2005: 205A–205A

- **Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation** *AMERICAN JOURNAL OF PATHOLOGY*
  Schimmelpfennig, C. H., Schulz, S., Arber, C., Baker, J., Tarner, I., McBride, J., Contag, C. H., Negrin, R. S.
  2005; 167 (5): 1321-1331

- **Protective conditioning for acute graft-versus-host disease** *NEW ENGLAND JOURNAL OF MEDICINE*
  Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., Shizuru, J. A., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Hoppe, R. T., Bloch, D. A., Blume, K. G., Negrin, et al
  2005; 353 (13): 1321-1331

- **In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets** *BLOOD*
  Beilhack, A., Schulz, S., Baker, J., Beilhack, G. F., Wieland, C. B., Herman, E. I., Baker, E. M., Cao, Y. A., Contag, C. H., Negrin, R. S.
  2005; 106 (3): 1113-1122

- **Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation** *TRANSPLANTATION*
  Cao, Y. A., Bachmann, M. H., Beilhack, A., Yang, Y., Tanaka, M., Swijnenburg, R. J., Reeves, R., Taylor-Edwards, C., Schulz, S., Doyle, T. C., Fathman, C. G., Robbins, R. C., Herzenberg, et al
  2005; 80 (1): 134-139

- **Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells** *CLINICAL CANCER RESEARCH*
  Verneris, M. R., Arshi, A., Edinger, M., Kornacker, M., Natkunam, Y., Karami, M., Cao, Y. A., Marina, N., Contag, C. H., Negrin, R. S.
  2005; 11 (12): 4561-4570

- **A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Leemhuis, T., Wells, S., Scheffold, C., Edinger, M., Negrin, R. S.
  2005; 11 (3): 181-187

- **Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Oehler, V. G., Radich, J. P., Storer, I., Blume, K. G., Chauncey, T., Clift, R., Snyder, D. S., Forman, S. J., Flowers, M. E., Martin, P., Guthrie, K. A., Negrin, R. S., Appelbaum, et al
  2005; 11 (2): 85-92

- **Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system** *ANNUAL REVIEW OF MEDICINE*
  Shizuru, J. A., Negrin, R. S., Weissman, I. L.
  2005; 56: 509-538

- **Immunoglobulin G Fc polymorphism is correlated with rituximab-induced neutropenia following autologous hematopoietic cell transplantation.** *46th Annual Meeting of the American-Society-of-Hematology*
  Weng, W. K., Horning, S. J., Negrin, R. S., Levy, R.
  AMER SOC HEMATOLOGY.2004: 129A–129A

- **In vivo trafficking of CD4+CD25+ regulatory T-cells in allogeneic recipients using bioluminescence imaging.** *46th Annual Meeting of the American-Society-of-Hematology*
  Nguyen, V. H., Wieland, C., Contag, C., Negrin, R. S.
  AMER SOC HEMATOLOGY.2004: 90A–90A

- **Silensilencing human NKG2D, DAP10 and DAP12 reduces cytotoxicity of in vivo activated CD8(+) T and NK cells** *46th Annual Meeting of the American-Society-of-Hematology*
  Karimi, M. A., Cao, T., Verneris, M. R., Baker, J., Negrin, R. S.
  AMER SOC HEMATOLOGY.2004: 130A–131A

- **Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8(+) T cells** *BLOOD*

Verneris, M. R., Karami, M., Baker, J., Jayaswal, A., Negrin, R. S.
2004; 103 (8): 3065-3072

- **In vivo dynamics of hematopoietic reconstitution from purified stem and progenitor cells.** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
  Wagers, A. J., Cao, Y. A., Beilhack, A., Dusich, J., Bachmann, M. H., Negrin, R. S., Weissman, I. L., Contag, C. H.
  AMER SOC HEMATOLOGY.2003: 332A–332A
- **Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects against lethal acute graft versus host disease.**
  Dutt, S., Ermann, J., Hoffmann, P., Edinger, M., Negrin, R. S., Fathman, C. G., Strober, S.
  AMER SOC HEMATOLOGY.2003: 950A
- **In vivo trafficking of activated T cells in allogeneic recipients using bioluminescent imaging.** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
  Wieland, C. B., Beilhack, A., Baker, J., Cao, Y. A., Herman, E., Baker, E., Contag, C. H., Negrin, R. S.
  AMER SOC HEMATOLOGY.2003: 948A–948A
- **Evaluation of effector cell fate and function by in vivo bioluminescence imaging** *METHODS*
  Edinger, M., Hoffmann, P., Contag, C. H., Negrin, R. S.
  2003; 31 (2): 172-179
- **CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation** *NATURE MEDICINE*
  Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C. G., Strober, S., Negrin, R. S.
  2003; 9 (9): 1144-1150
- **Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging** *BLOOD*
  Edinger, M., Cao, Y. A., Verneris, M. R., Bachmann, M. H., Contag, C. H., Negrin, R. S.
  2003; 101 (2): 640-648
- **Advancing animal models of neoplasia through in vivo bioluminescence imaging** *EUROPEAN JOURNAL OF CANCER*
  Edinger, M., Cao, Y. A., Hornig, Y. S., Jenkins, D. E., Verneris, M. R., Bachmann, M. H., Negrin, R. S., Contag, C. H.
  2002; 38 (16): 2128-2136
- **Visualization of effective tumor targeting by CD8+natural killer T cells redirected with bispecific antibody F(ab ')(2)HER2xCD3** *CANCER RESEARCH*
  Scheffold, C., Kornacker, M., Scheffold, Y. C., Contag, C. H., Negrin, R. S.
  2002; 62 (20): 5785-5791
- **Studies of ex vivo activated and expanded CD8(+) NK-T cells in humans and mice** *Sass-Foundation Research Conference on New Frontiers in Biological Therapy for Hematological Malignancies*
  Verneris, M. R., Baker, J., Edinger, M., Negrin, R. S.
  SPRINGER/PLENUM PUBLISHERS.2002: 131–36
- **Understanding immune cell trafficking patterns via in vivo bioluminescence imaging** *JOURNAL OF CELLULAR BIOCHEMISTRY*
  Mandl, S., Schimmelpfennig, C., Edinger, M., Negrin, R. S., Contag, C. H.
  2002: 239-248
- **Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence** *3rd International Symposium on Transplantation in Hematology and Oncology*
  Negrin, R. S., Edinger, M., Verneris, M., Cao, Y. A., Bachmann, M., Contag, C. H.
  SPRINGER.2002: S44–S45
- **Bioluminescence imaging of lymphocyte trafficking in vivo** *EXPERIMENTAL HEMATOLOGY*
  Hardy, J., Edinger, M., Bachmann, M. H., Negrin, R. S., Fathman, C. G., Contag, C. H.
  2001; 29 (12): 1353-1360
- **Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas.**
  Horwitz, S. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Stuart, M. J., Breslin, S., Blume, K. G., Horning, S. J.
  AMER SOC HEMATOLOGY.2001: 862A–862A

- **Bisphosphonate and IPP expanded gamma delta T cells have in vitro and in vivo antitumor function.**
  Baker, J., Verneris, M. R., Kivivuori, S. M., Schimmelpfennig, C. H., Negrin, R. S.
  AMER SOC HEMATOLOGY.2001: 167A–167A

- **Characterization of ex vivo expanded gamma/delta T cells.**
  Kivivuori, S. M., Verneris, M. R., Baker, J., Negrin, R. S.
  AMER SOC HEMATOLOGY.2001: 235A–235A

- **Autologous stem cell transplantation for high-risk adult acute lymphomblastic leukemia (ALL).**
  Linker, C., Damon, L., Navarro, W., Ries, C., Negrin, R., Blume, K., Synder, D., Forman, S.
  AMER SOC HEMATOLOGY.2001: 689A

- **Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis** *INTERNATIONAL JOURNAL OF CANCER*
  Kornacker, M., Schlattner, U., Wallimann, T., Verneris, M. R., Negrin, R. S., Kornacker, B., Staratschek-Jox, A., Diehl, V., Wolf, J.
  2001; 94 (4): 513-519

- **Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+cells in patients with advanced hematologic malignancies** *CANCER*
  Cao, T. M., Kusnierz-Glaz, C., Valone, F., Stockerl-Goldstein, K. E., Hu, W. W., Johnston, L., Blume, K. G., Strober, S., Negrin, R. S.
  2001; 91 (12): 2205-2213

- **Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production** *BLOOD*
  Baker, J., Verneris, M. R., Ito, M., Shizuru, J. A., Negrin, R. S.
  2001; 97 (10): 2923-2931

- **Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells** *IMMUNOLOGY LETTERS*
  Kornacker, M., Verneris, M. R., Kornacker, B., Scheffold, C., Negrin, R. S.
  2001; 76 (3): 169-173

- **CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56(+) T cells** *CANCER IMMUNOLOGY IMMUNOTHERAPY*
  Lopez, R. D., Waller, E. K., Lu, P. H., Negrin, R. S.
  2001; 49 (12): 629-640

- **Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.** *NEW ENGLAND JOURNAL OF MEDICINE*
  Bensinger, W. I., Martin, P. J., Storer, B., Clift, R., Forman, S. J., Negrin, R., Kashyap, A., Flowers, M. E., Lilleby, K., Chauncey, T. R., STORB, R., Appelbaum, F. R., Rowley, et al
  2001; 344 (3): 175-181

- **High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial** *BLOOD*
  Horning, S. J., Negrin, R. S., Hoppe, R. T., Rosenberg, S. A., Chao, N. J., Long, G. D., Brown, B. W., Blume, K. G.
  2001; 97 (2): 404-409

- **High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., Taylor, T. L., Shizuru, J. A., Hoppe, R. T., Brown, B. W., Blume, K. G., Stockerl-Goldstein, K.
  2001; 7 (5): 294-301

- **Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Alvarnas, J. C., Linn, Y. C., Hope, E. G., Negrin, R. S.
  2001; 7 (4): 216-222

- **CD31 mismatching affects marrow transplantation outcome** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  GRUMET, F. C., Hiraki, D. D., Brown, B. W., Zehnder, J. L., Zacks, E. S., Draksharapu, A., Parnes, J., Negrin, R. S.

2001; 7 (9): 503-512

- **Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Stuart, M. J., Chao, N. S., Horning, S. J., Wong, R. M., Negrin, R. S., JOHNSTON, L. J., Shizuru, J. A., Long, G. D., Blume, K. G., Stockerl-Goldstein, K. E., Goldstein, S.
  2001; 7 (10): 552-560

- **Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Verneris, M. R., Ito, M., Baker, E., Arshi, A., Negrin, R. S., Shizuru, J. A.
  2001; 7 (10): 532-542

- **CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies** *BLOOD*
  Lopez, R. D., Xu, S., Guo, B., Negrin, R. S., Waller, E. K.
  2000; 96 (12): 3827-3837

- **Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications.**
  Horwitz, S. M., Breslin, S., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Taylor, T., Brown, B. W., Blume, K. G., Horning, S. J.
  AMER SOC HEMATOLOGY.2000: 384A–384A

- **High dose therapy and autologous hematopoietic cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience.**
  Cao, T. M., Negrin, R. S., Hu, W. W., JOHNSTON, L. J., Taylor, T. L., Shizuru, J. A., Brown, B. W., Horning, S. J., Blume, K. G., Stockerl-Goldstein, K. E.
  AMER SOC HEMATOLOGY.2000: 482A–482A

- **Resistance of ex vivo expanded CD3(+)CD56(+) T cells to Fas-mediated apoptosis** *CANCER IMMUNOLOGY IMMUNOTHERAPY*
  Verneris, M. R., Kornacker, M., Mailander, V., Negrin, R. S.
  2000; 49 (6): 335-345

- **Effect of oral glutamine supplementation during bone marrow transplantation** *JOURNAL OF PARENTERAL AND ENTERAL NUTRITION*
  Dickson, T. M., Wong, R. M., Negrin, R. S., Shizuru, J. A., JOHNSTON, L. J., Hu, W. W., Blume, K. G., Stockerl-Goldstein, K. E.
  2000; 24 (2): 61-66

- **Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Stockerl-Goldstein, K. E., Reddy, S. A., Horning, S. J., Blume, K. G., Chao, N. J., Hu, W. W., JOHNSTON, L. J., Long, G. D., Strober, S., Wong, R. M., Feiner, R. H., Kohler, S., Negrin, et al
  2000; 6 (5): 506-512

- **Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: Results of a prospective double-blind randomized trial** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Chao, N. J., Snyder, D. S., Jain, M., Wong, R. M., Niland, J. C., Negrin, R. S., Long, G. D., Hu, W. W., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Amylon, M. D., Tierney, D. K., O'Donnell, et al
  2000; 6 (3): 254-261

- **A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Nash, R. A., Kurzrock, R., DiPersio, J., Vose, J., Linker, C., Maharaj, D., Nademanee, A. P., Negrin, R., Nimer, S., Shulman, H., Ashby, M., Jones, D., Appelbaum, et al
  2000; 6 (1): 25-34

- **Transplantation of highly purified CD34(+)Thy-l+ hematopoietic stem cells in patients with metastatic breast cancer** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Negrin, R. S., Atkinson, K., Leemhuis, T., Hanania, E., Juttner, C., Tierney, K., Hu, W. W., JOHNSTON, L. J., Shizuru, J. A., Stockerl-Goldstein, K. E., Blume, K. G., Weissman, I. L., Bower, et al
  2000; 6 (3): 262-271

- **Use of reporter genes for optical measurements of neoplastic disease in vivo** *NEOPLASIA*
  Contag, C. H., Jenkins, D., Contag, F. R., Negrin, R. S.
  2000; 2 (1-2): 41-52

- **Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Hu, W. W., Negrin, R. S., Stockerl-Goldstein, K., JOHNSTON, L. J., Shizuru, J. A., Wong, R. M., Chao, N. J., Long, G. D., Feiner, R. H., Blume, K. G.
  2000; 6 (1): 58-69

- **High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Alvarnas, J. C., Negrin, R. S., Horning, S. J., Hu, W. W., Long, G. D., Schriber, J. R., Stockerl-Goldstein, K., Tierney, K., Wong, R., Blume, K. G., Chao, N. J.
  2000; 6 (3A): 352-358

- **Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic tell transplantation precludes its use in refractory/ recurrent non-Hodgkin's lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Johnston, L. J., Stockerl-Goldstein, K. E., Hu, W. W., Negrin, R. S., Hoppe, R. T., Blume, K. G., Horning, S. J.
  2000; 6 (5A): 555-562

- **Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Cao, T. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Taylor, T. L., Rizk, N. W., Wong, R. M., Blume, K. G., Hu, W. W.
  2000; 6 (4): 387-394

- **Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission** *LEUKEMIA*
  Snyder, D. S., Nademanee, A. P., O'Donnell, M. R., Parker, P. M., Stein, A. S., Margolin, K., Somlo, G., Molina, A., Spielberger, R., Kashyap, A., Fung, H., Slovak, M. L., Dagis, et al
  1999; 13 (12): 2053-2058

- **Increased transplant-related mortality following high-dose sequential chemotherapy and autologous hematopoietic cell transplantation (AHCT) using the Ceprate SC stem cell concentration system for multiple myeloma (MM).**
  Stockerl-Goldstein, K. E., Brown, J. M., O'Brien, R. M., Negrin, R. S., Hu, W. W., JOHNSTON, L. J., Shizuru, J. A., Taylor, T. L., Blume, K. G.
  AMER SOC HEMATOLOGY.1999: 608A–608A

- **Survivin expression is found preferentially in memory T-cells and correlates with apoptosis resistance after lymphocyte activation.**
  Kornacker, M., Verneris, M. R., Kornacker, B., Scheffold, C., Negrin, R. S.
  AMER SOC HEMATOLOGY.1999: 8A

- **A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer** *CLINICAL CANCER RESEARCH*
  Hu, W. W., Long, G. D., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Chao, N. J., Negrin, R. S., Blume, K. G.
  1999; 5 (11): 3411-3418

- **Visualizing the kinetics of tumor-cell clearance in living animals** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Sweeney, T. J., Mailander, V., Tucker, A. A., Olomu, A. B., Zhang, W. S., Cao, Y. A., Negrin, R. S., Contag, C. H.
  1999; 96 (21): 12044-12049

- **Noninvasive assessment of tumor cell proliferation in animal models.** *Neoplasia*
  Edinger, M., Sweeney, T. J., Tucker, A. A., Olomu, A. B., Negrin, R. S., Contag, C. H.
  1999; 1 (4): 303-310

- **Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation** *BLOOD*
  Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., Velardi, A.
  1999; 94 (1): 333-339

- **Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation.** *Biology of blood and marrow transplantation*
  Dickson, T. M., Kusnierz-Glaz, C. R., Blume, K. G., Negrin, R. S., Hu, W. W., Shizuru, J. A., Johnston, L. L., Wong, R. M., Stockerl-Goldstein, K. E.

1999; 5 (5): 299-305

- **Assays to determine hematopoietic stem cell content in blood or marrow grafts.** *Cytotherapy*
  Verfaillie, C. M., Ploemacher, R., di Persio, J., Sutherland, R., Serke, S., Johnsen, H., Noga, S., Negrin, R.
  1999; 1 (1): 41-49

- **ISHAGE Scientific Committee Report - Assays to determine hematopoietic stem cell content in blood or marrow grafts** *CYTOTHERAPY*
  Verfaillie, C. M., Ploemacher, R., di Persio, J., Sutherland, R., Serke, S., Johnsen, H., Noga, S., Negrin, R.
  1999; 1 (1): 41-49

- **Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.** *Biology of blood and marrow transplantation*
  Ross, M., Schmidt, G. M., Niland, J. C., Amylon, M. D., Dagis, A. C., Long, G. D., Nademanee, A. P., Negrin, R. S., O'Donnell, M. R., Parker, P. M., Smith, E. P., Snyder, D. S., Stein, et al
  1999; 5 (5): 285-291

- **Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice** *BLOOD*
  Hoyle, C., Bangs, C. D., Chang, P., Kamel, O., Mehta, B., Negrin, R. S.
  1998; 92 (9): 3318-3327

- **Minimal residual disease.** *Current opinion in hematology*
  Negrin, R. S.
  1998; 5 (6): 488-493

- **Engraftment of chronic myeloid leukemia in SCID mice** *HEMATOLOGICAL ONCOLOGY*
  Hoyle, C. F., Negrin, R. S.
  1998; 16 (3): 87-100

- **A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation** *BLOOD*
  Bernstein, S. H., Nademanee, A. P., Vose, J. M., Tricot, G., Fay, J. W., Negrin, R. S., DiPersio, J., Rondon, G., Champlin, R., Barnett, M. J., Cornetta, K., Herzig, G. P., Vaughan, et al
  1998; 91 (9): 3509-3517

- **Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.** *Biology of blood and marrow transplantation*
  Long, G. D., Amylon, M. D., Stockerl-Goldstein, K. E., Negrin, R. S., Chao, N. J., Hu, W. W., Nademanee, A. P., Snyder, D. S., Hoppe, R. T., Vora, N., Wong, R., Niland, J., Reichardt, et al
  1997; 3 (6): 324-330

- **Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model** *BRITISH JOURNAL OF HAEMATOLOGY*
  HELLSTROMLINDBERG, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., Ost, A., Greenberg, P.
  1997; 99 (2): 344-351

- **Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation.** *Biology of blood and marrow transplantation*
  Lu, P. H., Negrin, R. S.
  1997; 3 (3): 113-121

- **Cellular immunotherapy and autologous transplantation for hematologic malignancy** *IMMUNOLOGICAL REVIEWS*
  Margolin, K. A., Negrin, R. S., Wong, K. K., Chatterjee, S., Wright, C., Forman, S. J.
  1997; 157: 231-240

- **Granulocyte colony-stimulating factor-induced comobilization of CD4(-)CD8(-) T cells and hematopoietic progenitor cells (CD34(+)) in the blood of normal donors** *BLOOD*
  KUSNIERZGLAZ, C. R., Still, B. J., Amano, M., Zukor, J. D., Negrin, R. S., Blume, K. G., Strober, S.
  1997; 89 (7): 2586-2595

- **High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices** *BLOOD*
  Horning, S. J., Chao, N. J., Negrin, R. S., Hoppe, R. T., Long, G. D., Hu, W. W., Wong, R. M., Brown, B. W., Blume, K. G.

1997; 89 (3): 801-813

- **Activated T cells and cytokine-induced CD3(+)CD56(+) killer cells** *ANNALS OF HEMATOLOGY*
  SCHMIDTWOLF, G. D., Negrin, R. S., SCHMIDTWOLF, I. G.
  1997; 74 (2): 51-56

- **Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies** *Annual Meeting of the German-and-Austrian-Society-of-Hematology-and-Oncology*
  KUSNIERZGLAZ, C. R., Schlegel, P. G., Wong, R. M., Schriber, J. R., Chao, N. J., Amylon, M. D., Hu, W. W., Negrin, R. S., Lee, Y. S., Blume, K. G., Long, G. D.
  AMER SOC CLINICAL ONCOLOGY.1997: 18–25

- **High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma** *CANCER*
  Long, G. D., Chao, N. J., Hu, W. W., Negrin, R. S., Wong, R. M., Blume, K. G.
  1996; 78 (12): 2502-2509

- **Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy** *BLOOD*
  Negrin, R. S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S., Greenberg, P. L.
  1996; 87 (10): 4076-4081

- **Leukemic burden in subpopulations of CD34(+) cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia** *BLOOD*
  Vandenberg, D., WESSMAN, M., Murray, L., Tong, J., Chen, B., Chen, S., Simonetti, D., KING, J., Yamasaki, G., DIGIUSTO, R., Carella, A., Frassoni, F., Gorin, et al
  1996; 87 (10): 4348-4357

- **Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.** *Biology of blood and marrow transplantation*
  Chao, N. J., Parker, P. M., Niland, J. C., Wong, R. M., Dagis, A., Long, G. D., Nademanee, A. P., Negrin, R. S., Snyder, D. S., Hu, W. W., Gould, K. A., Tierney, D. K., Zwingenberger, et al
  1996; 2 (2): 86-92

- **Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.** *Biology of blood and marrow transplantation*
  Stockerl-Goldstein, K. E., Horning, S. J., Negrin, R. S., Chao, N. J., Hu, W. W., Long, G. D., Hoppe, R. T., Amylon, M. D., BROWN, B. W., Wong, R. M., Blume, K. G.
  1996; 2 (2): 76-85

- **Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells** *CELLULAR IMMUNOLOGY*
  SCHMIDTWOLF, I. G., Lefterova, P., Johnston, V., Scheffold, C., Csipai, M., Mehta, B. A., Tsuruo, T., Huhn, D., Negrin, R. S.
  1996; 169 (1): 85-90

- **Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma** *CLINICAL CANCER RESEARCH*
  Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., Liles, T. M., GRILLOLOPEZ, A., Chinn, P., Varns, C., Ning, S. C., Fowler, S., Deb, N., Becker, et al
  1996; 2 (3): 457-470

- **Enrichment of allogeneic CD34+ cells and T cell depletion by percoll density gradient centrifugation** *1st International Symposium on Allogeneic Peripheral Blood Precursor Cell Transplants*
  Negrin, R. S., KUSNIERZGLAZ, C., Blume, K. G., Strober, S.
  STOCKTON PRESS.1996: S31–S33

- **BUSULFAN/CYCLOPHOSPHAMIDE AS CONDITIONING REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MYELODYSPLASIA** *JOURNAL OF CLINICAL ONCOLOGY*
  ODONNELL, M. R., Long, G. D., Parker, P. M., Niland, J., Nademanee, A., Amylon, M., Chao, N., Negrin, R. S., Schmidt, G. M., Slovak, M. L., Smith, E. P., Snyder, D. S., Stein, et al
  1995; 13 (12): 2973-2979

- **THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE** *BLOOD*
  Parker, P. M., Chao, N., Nademanee, A., ODONNELL, M. R., Schmidt, G. M., Snyder, D. S., Stein, A. S., Smith, E. P., Molina, A., Stepan, D. E., Kashyap, A., Planas, I., Spielberger, et al

1995; 86 (9): 3604-3609

- **2 PATHWAYS OF EXOCYTOSIS OF CYTOPLASMIC GRANULE CONTENTS AND TARGET-CELL KILLING BY CYTOKINE-INDUCED CD3(+)CD56(+) KILLER-CELLS** *BLOOD*
  Mehta, B. A., SCHMIDTWOLF, G. H., Weissman, I. L., Negrin, R. S.
  1995; 86 (9): 3493-3499

- **MULTIPLE CYCLES OF HIGH-DOSE CHEMOTHERAPY SUPPORTED BY HEMATOPOIETIC PROGENITOR CELLS AS TREATMENT FOR PATIENTS WITH ADVANCED MALIGNANCIES** *CANCER*
  Long, G. D., Negrin, R. S., Hoyle, C. F., KUSNIERZGLAZ, C. R., Schriber, J. R., Blume, K. G., Chao, N. J.
  1995; 76 (5): 860-868

- **ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION** *EXPERIMENTAL HEMATOLOGY*
  Schriber, J. R., DEJBAKHSHJONES, S., KUSNIERZGLAZ, C. R., Ginzton, N., Still, B., Negrin, R. S., Greenberg, P., Strober, S.
  1995; 23 (9): 1024-1029

- **TRANSPLANTATION OF ENRICHED AND PURGED PERIPHERAL-BLOOD PROGENITOR CELLS FROM A SINGLE APHERESIS PRODUCT IN PATIENTS WITH NON-HODGKINS-LYMPHOMA** *BLOOD*
  Negrin, R. S., KUSNIERZGLAZ, C. R., Still, B. J., Schriber, J. R., Chao, N. J., Long, G. D., Hoyle, C., Hu, W. W., Horning, S. J., Brown, B. W., Blume, K. G., Strober, S.
  1995; 85 (11): 3334-3341

- **IS NITROUS-OXIDE SAFE FOR BONE-MARROW HARVEST** *ANESTHESIA AND ANALGESIA*
  Lederhaas, G., BROCKUTNE, J. G., Negrin, R. S., Riley, E., Brodsky, J. B.
  1995; 80 (4): 770-772

- **A NEW PREPARATORY REGIMEN FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA** *CANCER*
  Chao, N. J., Kastrissios, H., Long, G. D., Negrin, R. S., Horning, S. J., Wong, R. M., Blaschke, T. F., Blume, K. G.
  1995; 75 (6): 1354-1359

- **ENRICHMENT OF HUMAN HEMATOPOIETIC STEM-CELL ACTIVITY IN THE CD34(+)THY-1(+)LIN(-) SUBPOPULATION FROM MOBILIZED PERIPHERAL-BLOOD** *BLOOD*
  Murray, L., Chen, B., Galy, A., Chen, S., Tushinski, R., Uchida, N., Negrin, R., Tricot, G., Jagannath, S., Vesole, D., Barlogie, B., Hoffman, R., Tsukamoto, et al
  1995; 85 (2): 368-378

- **EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES** *LEUKEMIA*
  Nagler, A., MacKichan, M. L., Negrin, R. S., Donlon, T., Greenberg, P. L.
  1995; 9 (1): 30-39

- **FRACTIONATED TOTAL-BODY IRRADIATION, ETOPOSIDE, AND CYCLOPHOSPHAMIDE PLUS AUTOGRAFTING IN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA** *JOURNAL OF CLINICAL ONCOLOGY*
  Horning, S. J., Negrin, R. S., Chao, N. J., Long, G. D., Hoppe, R. T., Blume, K. G.
  1994; 12 (12): 2552-2558

- **ESTABLISHMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) IN SCID MICE**
  HOYLE, C., NEGRIN, R. S.
  W B SAUNDERS CO.1994: A493

- **INTERLEUKIN-12 PROMOTES THE EXPANSION OF CD3+CD56+ KILLER-CELLS DERIVED FROM CD3+CD56- T-CELLS WITH ENHANCED CYTOTOXICITY**
  LU, P. H., NEGRIN, R. S.
  W B SAUNDERS CO.1994: A289

- **GRANULOCYTE-COLONY-STIMULATING FACTOR AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION** *BLOOD*
  Schriber, J. R., Chao, N. J., Long, G. D., Negrin, R. S., Tierney, D. K., KUSNIERZGLAZ, C., Lucas, K. S., Blume, K. G.
  1994; 84 (5): 1680-1684

- **FRACTIONATED TOTAL-BODY IRRADIATION AND HIGH-DOSE ETOPOSIDE AS A PREPARATORY REGIMEN FOR BONE-MARROW TRANSPLANTATION FOR 94 PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE** *BLOOD*

Snyder, D. S., Negrin, R. S., ODONNELL, M. R., Chao, N. J., Amylon, M. D., Long, G. D., Nademanee, A. P., Stein, A. S., Parker, P. M., Smith, E. P., Somlo, G., Margolin, K., Molina, et al
1994; 84 (5): 1672-1679

- **A NOVEL POPULATION OF EXPANDED HUMAN CD3+CD56+ CELLS DERIVED FROM T-CELLS WITH POTENT IN-VIVO ANTITUMOR-ACTIVITY IN MICE WITH SEVERE COMBINED IMMUNODEFICIENCY** *JOURNAL OF IMMUNOLOGY*
  Lu, P. H., Negrin, R. S.
  1994; 153 (4): 1687-1696

- **PROPAGATION OF LARGE NUMBERS OF T-CELLS WITH NATURAL-KILLER-CELL MARKERS** *BRITISH JOURNAL OF HAEMATOLOGY*
  SCHMIDTWOLF, I. G., Lefterova, P., Johnston, V., Huhn, D., Blume, K. G., Negrin, R. S.
  1994; 87 (3): 453-458

- **GENERATION OF T-CELLS FROM CYTOKINE-MOBILIZED PERIPHERAL-BLOOD AND ADULT BONE-MARROW CD34+ CELLS** *BLOOD*
  Galy, A. H., Webb, S., CEN, D. H., Murray, L. J., CONDINO, J., Negrin, R. S., Chen, B. P.
  1994; 84 (1): 104-110

- **A RANDOMIZED STUDY OF ERYTHROPOIETIN AND GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) VERSUS PLACEBO AND G-CSF FOR PATIENTS WITH HODGKINS AND NON-HODGKINS-LYMPHOMA UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION** *BLOOD*
  Chao, N. J., Schriber, J. R., Long, G. D., Negrin, R. S., CATOLICO, M., Brown, B. W., MILLER, L. L., Blume, K. G.
  1994; 83 (10): 2823-2828

- **DETECTION OF TUMOR-CELLS IN PURGED BONE-MARROW AND PERIPHERAL-BLOOD MONONUCLEAR-CELLS BY POLYMERASE CHAIN-REACTION AMPLIFICATION OF BCL-2 TRANSLOCATIONS** *JOURNAL OF CLINICAL ONCOLOGY*
  Negrin, R. S., PESANDO, J.
  1994; 12 (5): 1021-1027

- **THE ROLE OF N-LINKED CARBOHYDRATE RESIDUES IN LYMPHOKINE-ACTIVATED KILLER CELL-MEDIATED CYTOLYSIS** *CELLULAR IMMUNOLOGY*
  Mehta, B. A., Collard, H. R., Negrin, R. S.
  1994; 155 (1): 95-110

- **MUTATIONS IN THE RAS PROTOONCOGENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES** *LEUKEMIA*
  Neubauer, A., Greenberg, P., Negrin, R., Ginzton, N., Liu, E.
  1994; 8 (4): 638-641

- **ROLE OF ETOPOSIDE (VP-16) IN PREPARATORY REGIMENS FOR PATIENTS WITH LEUKEMIA OR LYMPHOMA UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION** *Symposium on Allogeneic Bone Marrow Transplantation - State of the Art and Future Directions*
  Blume, K. G., Long, G. D., Negrin, R. S., Chao, N. J., KUSNIERZGLAZ, C., Amylon, M. D.
  STOCKTON PRESS.1994: S9–S10

- **ANALYSIS OF HUMAN HEMATOPOIETIC STEM-CELL POPULATIONS** *BLOOD CELLS*
  Murray, L., DiGiusto, D., Chen, B., Chen, S., Combs, J., Conti, A., Galy, A., Negrin, R., Tricot, G., Tsukamoto, A.
  1994; 20 (2-3): 364-370

- **PHENOTYPIC CHARACTERIZATION AND IDENTIFICATION OF EFFECTOR-CELLS INVOLVED IN TUMOR-CELL RECOGNITION OF CYTOKINE-INDUCED KILLER-CELLS** *EXPERIMENTAL HEMATOLOGY*
  SCHMIDTWOLF, I. G., Lefterova, P., Mehta, B. A., Fernandez, L. P., HUHN, L. D., Blume, K. G., Weissman, I. L., Negrin, R. S.
  1993; 21 (13): 1673-1679

- **MULTIPLE HIGH-DOSE CHEMOTHERAPY CYCLES SUPPORTED BY PERIPHERAL-BLOOD PROGENITOR CELLS AND G-CSF**
  CHAO, N. J., LONG, G. D., NEGRIN, R. S., KUZNIERZGLAS, C., BLUME, K. G.
  W B SAUNDERS CO.1993: A349

- **A NEW PREPARATORY REGIMEN FOR BONE-MARROW TRANSPLANTATION FOR HODGKINS AND NON-HODGKINS-LYMPHOMA - CCNU (LOMUSTINE) ETOPOSIDE CYCLOPHOSPHAMIDE**
  CHAO, N. J., LONG, G. D., NEGRIN, R. S., BLUME, K. G.
  W B SAUNDERS CO.1993: A143

- **GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION**
  SCHRIBER, CHAO, N. J., LONG, G. D., NEGRIN, R. S., BLUME, K. G.
  W B SAUNDERS CO.1993: A286

- **Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission.** *Blood*
  Snyder, D. S., Chao, N. J., Amylon, M. D., Taguchi, J., Long, G. D., Negrin, R. S., Nademanee, A. P., O'Donnell, M. R., Schmidt, G. M., Stein, A. S.
  1993; 82 (9): 2920-2928

- **FRACTIONATED TOTAL-BODY IRRADIATION AND HIGH-DOSE ETOPOSIDE AS A PREPARATORY REGIMEN FOR BONE-MARROW TRANSPLANTATION FOR 99 PATIENTS WITH ACUTE-LEUKEMIA IN 1ST COMPLETE REMISSION** *BLOOD*
  Snyder, D. S., Chao, N. J., Amylon, M. D., Taguchi, J., Long, G. D., Negrin, R. S., Nademanee, A. P., ODONNELL, M. R., Schmidt, G. M., Stein, A. S., Parker, P. M., Smith, E. P., Stepan, et al
  1993; 82 (9): 2920-2928

- **EFFICIENT GENERATION AND CHARACTERIZATION OF TUMOR-CELL SUBCLONES WITH DIFFERENT ADHESION PATHWAYS INVOLVED IN CELL-LYSIS** *HAEMATOLOGICA*
  Lefterova, P., Negrin, R., Neubauer, A., Huhn, D., Blume, K., SCHMIDTWOLF, I.
  1993; 78 (6): 353-358

- **CYCLOSPORINE, METHOTREXATE, AND PREDNISONE COMPARED WITH CYCLOSPORINE AND PREDNISONE FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE** *NEW ENGLAND JOURNAL OF MEDICINE*
  Chao, N. J., Schmidt, G. M., Niland, J. C., Amylon, M. D., Dagis, A. C., Long, G. D., Nademanee, A. P., Negrin, R. S., ODONNELL, M. R., Parker, P. M., Smith, E. P., Snyder, D. S., Stein, et al
  1993; 329 (17): 1225-1230

- **THE EFFICACY OF GRANULOCYTE-COLONY-STIMULATING FACTOR FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA WITH MONOCLONAL-ANTIBODY PURGED BONE-MARROW** *LEUKEMIA*
  Schriber, J. R., Negrin, R. S., Chao, N. J., Long, G. D., Horning, S. J., Blume, K. G.
  1993; 7 (10): 1491-1495

- **TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN** *BLOOD*
  Negrin, R. S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., Krantz, S., Greenberg, P. L.
  1993; 82 (3): 737-743

- **USE AND TOXICITY OF THE COLONY-STIMULATING FACTORS** *DRUG SAFETY*
  Schriber, J. R., Negrin, R. S.
  1993; 8 (6): 457-468

- **GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS ACCELERATE GRANULOCYTE AND PLATELET RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY** *BLOOD*
  Chao, N. J., Schriber, J. R., Grimes, K., Long, G. D., Negrin, R. S., RAIMONDI, C. M., Horning, S. J., Brown, S. L., Miller, L., Blume, K. G.
  1993; 81 (8): 2031-2035

- **BUSULFAN ETOPOSIDE - INITIAL EXPERIENCE WITH A NEW PREPARATORY REGIMEN FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NONLYMPHOBLASTIC LEUKEMIA** *BLOOD*
  Chao, N. J., Stein, A. S., Long, G. D., Negrin, R. S., Amylon, M. D., Wong, R. M., Forman, S. J., Blume, K. G.
  1993; 81 (2): 319-323

- **THE USE OF COLONY STIMULATING FACTORS IN CLINICAL BONE-MARROW TRANSPLANTATION** *CURRENT OPINION IN IMMUNOLOGY*
  Negrin, R. S., Greenberg, P. L.
  1992; 4 (5): 567-570

- **DYNAMIC ASSESSMENT OF QUALITY-OF-LIFE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION** *BLOOD*
  Chao, N. J., Tierney, D. K., Bloom, J. R., Long, G. D., Barr, T. A., STALLBAUM, B. A., Wong, R. M., Negrin, R. S., Horning, S. J., Blume, K. G.
  1992; 80 (3): 825-830

- **G-CSF AND PERIPHERAL-BLOOD PROGENITOR CELLS** *LANCET*
  Chao, N. J., Long, G. D., Negrin, R. S., Schriber, J. R., RAIMONDI, C. M., Brown, S. L., Blume, K. G.
  1992; 339 (8806): 1410-1410

- **Use of the polymerase chain reaction for the detection of tumor cell involvement of bone marrow and peripheral blood: implications for purging.** *Journal of hematotherapy*
  Negrin, R. S.
  1992; 1 (4): 361-368

- **INVITRO AND INVIVO ACTIVITY OF MURINE LYMPHOKINE-ACTIVATED KILLER-CELLS AFTER CRYOPRESERVATION** *TRANSFUSION*
  SCHMIDTWOLF, I. G., Aihara, M., Negrin, R. S., Blume, K. G., Chao, N. J.
  1992; 32 (1): 42-45

- **Therapy of hematopoietic disorders with recombinant colony-stimulating factors.** *Advances in pharmacology (San Diego, Calif.)*
  Negrin, R. S., Greenberg, P. L.
  1992; 23: 263-296

- **USE OF A SCID MOUSE HUMAN LYMPHOMA MODEL TO EVALUATE CYTOKINE-INDUCED KILLER-CELLS WITH POTENT ANTITUMOR CELL-ACTIVITY** *JOURNAL OF EXPERIMENTAL MEDICINE*
  SCHMIDTWOLF, I. G., Negrin, R. S., Kiem, H. P., Blume, K. G., Weissman, I. L.
  1991; 174 (1): 139-149

- **USE OF THE POLYMERASE CHAIN-REACTION TO MONITOR THE EFFECTIVENESS OF EX VIVO TUMOR-CELL PURGING** *BLOOD*
  Negrin, R. S., Kiem, H. P., SCHMIDTWOLF, I. G., Blume, K. G., Cleary, M. L.
  1991; 77 (3): 654-660

- **THE STANFORD EXPERIENCE WITH HIGH-DOSE ETOPOSIDE CYTOREDUCTIVE REGIMENS AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA - PRELIMINARY DATA** *ANNALS OF ONCOLOGY*
  Horning, S. J., Chao, N. J., Negrin, R. S., Hoppe, R. T., Kwak, L. W., Long, G. D., STALLBAUM, B., OCONNOR, P., Blume, K. G.
  1991; 2: 47-50

- **IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF** *BLOOD*
  Nagler, A., Binet, C., MacKichan, M. L., Negrin, R., Bangs, C., Donlon, T., Greenberg, P.
  1990; 76 (7): 1299-1307

- **MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR** *BLOOD*
  Negrin, R. S., HAEUBER, D. H., Nagler, A., Kobayashi, Y., Sklar, J., Donlon, T., Vincent, M., Greenberg, P. L.
  1990; 76 (1): 36-43

- **EFFECTS OF CSFS IN PRELEUKEMIA** *3RD INTERNATIONAL SYMP ON MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA*
  Greenberg, P. L., Negrin, R., Nagler, A.
  STOCKTON PRESS.1990: 121–126

- **EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES** *LEUKEMIA*
  Nagler, A., Ginzton, N., Negrin, R., Bang, D., Donlon, T., Greenberg, P.
  1990; 4 (3): 193-202

- **Bone marrow transplantation for hematologic malignancies: the Stanford experience.** *Clinical transplants*
  Chao, N. J., Amylon, M. D., Long, G. D., Negrin, R. S., Hoppe, R. T., Horning, S. J., Blume, K. G.
  1990: 157-163

- **EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR** *2ND INTERNATIONAL CONF ON BLOOD CELL GROWTH FACTORS : THEIR BIOLOGY AND CLINICAL APPLICATIONS*
  Greenberg, P., Negrin, R., Nagler, A., Vincent, M., Donlon, T.
  ALPHAMED PRESS.1990: 293–302

- **THE USE OF HEMATOPOIETIC GROWTH-FACTORS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES** *CANCER SURVEYS*
  Greenberg, P. L., Negrin, R., Nagler, A.
  1990; 9 (1): 199-212

- **EFFECTS OF TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR** *20TH ANNUAL SCIENTIFIC SYMP OF THE AMERICAN RED CROSS*
  Greenberg, P., Negrin, R., Nagler, A., Souza, L., Donlon, T.
  WILEY-LISS, INC.1990: 151–161
- **LYMPHOKINE-ACTIVATED KILLER CELL-ACTIVITY AFTER CRYOPRESERVATION** *JOURNAL OF IMMUNOLOGICAL METHODS*
  SCHMIDTWOLF, I. G., Aihara, M., Negrin, R. S., Blume, K. G., Chao, N. J.
  1989; 125 (1-2): 185-189
- **TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL** *ANNALS OF INTERNAL MEDICINE*
  Negrin, R. S., HAEUBER, D. H., Nagler, A., Olds, L. C., Donlon, T., SOUZA, L. M., Greenberg, P. L.
  1989; 110 (12): 976-984
- **NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE IN ATELECTASIS** *CHEST*
  Duncan, S. R., Negrin, R. S., Mihm, F. G., Guilleminault, C., Raffin, T. A.
  1987; 92 (4): 621-624